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ABSTRACT

Baseler, Laura J. Ph.D., Purdue University, August 2015. Comparative Respiratory Tract
Pathology of Emerging Viral Infections. Major Professors: Margaret Miller and Heinz
Feldmann.

Increases in the number of infectious disease outbreaks affecting humans have
been reported nearly every decade since the 1940’s. Many of these outbreaks have been
caused by emerging zoonotic viruses. It has recently been estimated that there are at least
320,000 viruses in mammals that have yet to be discovered, some of which may affect
humans. As humans continue to encroach upon previously isolated areas and have greater
contact with wildlife, it is likely that zoonotic viruses will continue to emerge. Since
many of these emerging viruses cause significant disease or death in humans it is vital
that we study their pathology and pathogenesis in order to detect patterns in their
mechanisms of disease, which could then be used to develop broad spectrum antivirals or
vaccines. As such, we focused our studies on two recently emerged viruses, Nipah virus
and the Middle East respiratory syndrome coronavirus (MERS-CoV), which have caused
significant respiratory disease and death in humans.
We used a Syrian hamster model to investigate whether differences in case
fatality rates and prevalence of respiratory disease reported for Nipah virus outbreaks in
Malaysia and Bangladesh were caused by intrinsic differences in the genomes of virus
isolates from these outbreaks. We showed that hamsters developed similar end-stage
respiratory lesions regardless of the Nipah virus isolate. These results suggest that

xiv
differences reported between the outbreaks in Malaysia and Bangladesh were not due to
viral genome heterogeneity. Rather, differences in transmission routes, viral dose,
availability of healthcare facilities or willingness to seek medical care early in the
infection may be responsible for the differences noted between these outbreaks.
Additionally, we used Syrian hamsters to elucidate the early pathogenesis of Nipah virus.
Nipah virus first targeted the lung and nasal cavity; virus replication was identified at 8
hours post inoculation (hpi). Virus then spread to the larynx and trachea. Even at 48 hpi
we did not detect infectious virus in the brain or infection of blood vessels in multiple
organs. Results suggest that early administration of antivirals into the respiratory tract
may prevent widespread infection of the vasculature and virus replication in the brain.
Since development of animal models is vital for studying novel viruses, we
evaluated the available animal models of MERS-CoV infection. We found that transgenic
mice expressing human dipeptidyl peptidase 4 were well-suited for screening antivirals
and vaccines. Rhesus macaques and common marmosets were both suitable for
transmission studies and confirming vaccine efficacy, while marmosets were ideal for
confirming antiviral efficacy. Additionally, we compared the rhesus macaque and
common marmoset models of MERS-CoV infection. We found that the increased clinical
disease severity observed in marmosets, as compared to macaques, was most likely
caused by increased pulmonary virus replication and development of more extensive
acute bronchointerstitial pneumonia. These results suggest that treatments aimed at
decreasing virus replication rates may dampen the acute pulmonary inflammatory
response, thus decreasing disease severity and potentially human case fatality rates.

1

CHAPTER 1. INTRODUCTION

1.1

Emerging Infectious Diseases

Increases in the number of infectious disease outbreaks affecting humans have been
reported nearly every decade since the 1940’s.80,108 Many of these outbreaks have been
caused by emerging infectious diseases, which include newly discovered diseases or
known diseases whose incidence or geographic distribution has reportedly
increased.14,37,102,147 The increase in the number of reported emerging infectious disease
outbreaks has predominantly been attributed to changes in how humans interact with their
environment. Increased international travel and trade have made it easier for infectious
diseases to spread globally, while deforestation, agricultural expansion and urban spread
have all allowed for increased contact between humans and wildlife.38,39 In fact, up to
75% of reported emerging infectious diseases are zoonotic pathogens, which often
originate in wildlife reservoirs, including bats.39,54,80,103,120,141,160 Emerging infectious
diseases can be transmitted from an animal reservoir to humans by multiple means; some
infectious diseases are thought to be transmitted directly to humans while others are
indirectly transmitted to humans by way of an intermediate animal host.24,81 Detection of
wildlife reservoirs is often complicated by the fact that these reservoirs are typically
asymptomatic or only develop mild disease.17,67,134 Unfortunately, transmission of these
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emerging infectious diseases to other species, including humans, can result in severe
disease.21,92
Although emerging infectious disease outbreaks can be caused by a wide array of
infectious entities, a large percentage of these outbreaks have been caused by viruses,
particularly RNA viruses.19,31,159,161 RNA viruses are more likely to cause emerging
infectious disease outbreaks than DNA viruses because RNA viruses lack proofreading
capabilities during genome replication, they have faster replication rates and a higher
propensity for spontaneous genetic mutations.46,53,74,158 Emerging RNA viruses that
specifically target the respiratory system can cause significant morbidity and
mortality.55,59,69 Two recent examples of emerging RNA viruses that cause respiratory
disease, and which will be reviewed further, are Nipah virus and the Middle East
respiratory syndrome coronavirus.

1.2

1.2.1

Nipah Virus

The Initial Outbreak

Nipah virus is a highly pathogenic biosafety level 4 (BSL-4) paramyxovirus in the
genus Henipavirus. This virus was first isolated from the cerebrospinal fluid from a fatal
human case during an outbreak that affected pigs and humans in 1998 to 1999; the initial
outbreak originated in Malaysia and subsequently spread to Singapore.26,117 (Figure 1.1)
During this outbreak, disease was first noted in pigs, followed by development of
symptoms in humans. Younger pigs predominantly experienced respiratory disease with
a characteristic barking cough, while adult pigs mainly presented with neurologic
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disease.101 Although, up to 100% of pigs on affected farms became infected, mortality
rates were low.101 In cases where necropsies were performed on pigs, interstitial
pneumonia, meningitis and widespread vascular damage were the main findings.101 Upon
isolation and identification of Nipah virus in pigs, a mass culling of approximately one
million pigs was performed by military personnel in Malaysia in order to end the
outbreak.7 Unfortunately, shipment of Nipah virus infected pigs from Malaysia to
Singapore, for slaughter, occurred prior to the culling of swine and resulted in the
infection of 11 abattoir workers in Singapore.117 The Nipah virus outbreak in Singapore
ended after importation of pigs from Malaysia was banned.24
In Malaysia and Singapore, the vast majority of affected humans were Chinese
men that worked on pig farms or had direct contact with pigs.8,22,60,135 Symptoms were
typically reported within two weeks of exposure to pigs; in some cases individuals
reported working with dying or sick pigs exhibiting respiratory disease, prior to onset of
their symptoms.60,116 Affected humans often developed a fever, encephalitis accompanied
by neurologic signs, headache or reduced levels of consciousness, and respiratory disease
that presented as a nonproductive cough and sore throat, which in some cases was
accompanied by abnormal chest radiographs and atypical pneumonia.22,26,49,60,117,144
Additional symptoms in some patients included myalgia, vomiting, hypertension, profuse
sweating and tachycardia.22,60 Lymphopenia, thrombocytopenia and hyperglycemia were
reported in some individuals.22,135 Nipah virus was isolated from tracheal secretions and
throat swabs, nasal secretions, cerebrospinal fluid and urine.28,29,60 During this outbreak,
265 human cases of Nipah virus infection were reported in Malaysia; the case fatality rate
was approximately 40%.116 Autopsies showed widespread vascular damage,
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predominantly within the brain and lung; vascular lesions were often associated with
infarcts and/or parenchymal inflammation.26,87 Affected blood vessels were characterized
by vasculitis, fibrin thrombi, fibrinoid change and/or formation of endothelial
syncytia.26,157 Occasionally, splenic lymphoid depletion, necrotizing splenitis and/or
lymphoid necrosis were observed.157

1.2.2

The Emergence of Nipah Virus in Bangladesh and India

Cases of Nipah virus infection in humans in Malaysia or Singapore have not been
identified since the initial outbreak ended in 1999; however, Nipah virus has emerged in
Bangladesh and India. The first outbreak in Bangladesh occurred in 2001 and almost
yearly outbreaks have been reported since.77,89,123 In India, Nipah virus outbreaks in
humans were detected in 2001 and 2007 in regions that bordered areas of Bangladesh
where outbreaks had previously been detected.10,18 In Bangladesh and India, there was no
evidence of illness in pigs prior to the detection of human cases of Nipah virus infection
and contact with pigs was not found to be a risk factor for Nipah virus infections in these
regions.77 Unlike the initial Nipah virus outbreak which mainly affected adult males, the
outbreaks in Bangladesh spanned a wide age range, from children to the elderly, and
typically involved both males and females.90,133 Similar to the outbreak in Malaysia and
Singapore, fever, encephalitis and respiratory disease were reported and occasional
development of gastrointestinal distress, including vomiting and diarrhea, was noted.76,123
Although a case fatality rate of up to 100% has been reported in individual outbreaks, no
autopsies have been performed on fatal human cases and descriptions of the histologic
lesions are not available for outbreaks in Bangladesh and India.155
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1.2.3

A Comparison of Nipah Virus Outbreaks

Although the outbreak in Malaysia and Singapore and the ongoing outbreaks in
Bangladesh and India were all caused by Nipah virus, key differences occurred in these
distinct geographic regions. Differences in the prevalence of respiratory disease, case
fatality rates, degree of genetic similarity among Nipah virus isolates, proposed routes of
transmission to humans and presence or absence of an intermediate host have been noted.
In the initial Nipah virus outbreak, respiratory disease was observed in close to 30% of
infected humans and the case fatality rate was approximately 40%.22,116,117 However, in
the outbreaks in Bangladesh and India both the prevalence of respiratory symptoms and
the case fatality rates were higher. In individual outbreaks, up to 75% of affected humans
developed respiratory disease and a case fatality rate of up to 100% was reported.10,132,155
There was minimal genetic heterogeneity among virus isolates from the Malaysia
outbreak; in fact, Nipah virus isolates from the lungs of infected pigs had genetic
sequences identical to those from humans.1,124 These results suggest that Nipah virus was
directly transmitted from pigs to humans and that perhaps there was only a single
introduction of Nipah virus into the pig population. Nipah virus isolates from the
Bangladesh outbreaks exhibited substantial genetic heterogeneity, suggesting that the
virus was spread to humans on several occasions and multiple isolates were circulating in
affected humans.86 Nipah virus isolates from Malaysia and Bangladesh were distantly
related. Although these virus isolates are considered to be one species, it has been
proposed that they represent two different genotypes since they share only 91.8%
nucleotide homology.68,124 However, genetic sequences from Nipah virus isolates in India
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and Bangladesh, two countries that border each other, were genetically similar enough to
suggest that they were derived from a common (bat) source.10,18
Differences have been noted in the proposed transmission cycles of Nipah virus in
Malaysia and Singapore as compared to Bangladesh and India. (Figure 1.2) In Malaysia,
flying foxes were thought to transmit the virus to pigs which acted as an intermediate,
amplifying host that transmitted Nipah virus to humans. Flying foxes, a type of bat, are
an asymptomatic reservoir host and excrete Nipah virus in their saliva and
urine.27,50,67,99,124,129,162,164 Pigsties in Malaysia are typically outdoors and some have been
located adjacent to fruit orchards, including those that grew mangos.122 It is suspected
that pigs became infected with Nipah virus after ingesting partially eaten mangos that
were contaminated by flying fox saliva laden with Nipah virus, after the fruit dropped
into an open air pigsty.25,144 Nipah virus then rapidly spread among pigs, likely through
contact with oral or respiratory secretions or urine.100 Humans were most likely infected
by direct contact with Nipah virus infected pigs and their secretions.8,20,116,144 In
Singapore, abattoir workers became infected when they contacted pigs imported from a
Nipah virus infected farm in Malaysia.117 Conversely, in the outbreaks in Bangladesh and
India, Nipah virus was thought to be transferred from fruit bats to humans with no
intermediate host.77 Flying foxes have been observed feeding from pots collecting date
palm sap in Bangladesh, potentially contaminating the sap with saliva or urine that
contained Nipah virus.90,123 Furthermore, human collection and ingestion of date palm
sap is seasonal, occurring from December to March, and coincides with the ongoing
outbreaks of Nipah virus.88 Humans likely became infected after they ingested raw date
palm sap contaminated with Nipah virus.90,123 Additionally, in Bangladesh and India,
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nosocomial and human-to-human transmission of Nipah virus have been reported,
usually after close contact with a human that was exhibiting respiratory
symptoms.18,64,75,132 Person to person transmission was not documented in the outbreak in
Malaysia and Singapore.104

1.2.4

Nipah Virus Tissue Tropism and Host Range

Although differences between Nipah virus outbreaks in various geographic
regions have been identified, the respiratory system, central nervous system, vasculature
and lymphoid system appeared to be consistently targeted. The tissue predilection
coincides with the locations of the receptors for Nipah virus, ephrin B2 and ephrin
B3.15,109,110 Receptors for Nipah virus have been detected on epithelial cells, arterial
endothelial cells, arterial smooth muscle cells, neurons and T lymphocytes.51,56,83,115,136,165
Ephrin B2 and ephrin B3 are highly conserved proteins, which may explain the broad
host range reported for Nipah virus.16,93 In addition to humans, pigs and flying foxes,
natural infections have also occasionally been detected in goats, horses, dogs and
cats.82,139,144 Additionally, several animal species are permissive to experimental Nipah
virus infections, including laboratory rodents, chicken embryos, cats, ferrets and
nonhuman primates; however, some of these models only recapitulate certain aspects of
Nipah virus infection. Animal models of Nipah virus infection will be briefly described.
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1.2.5

Animal Models of Nipah Virus Infection

1.2.5.1 Mouse Models of Nipah Virus Infection
Depending on the model, mice are either asymptomatic, exhibit respiratory and
vascular lesions or develop neurologic, respiratory and vascular disease. Intranasal
inoculation of wildtype C57BL/6 and BALB/c adult and young adult mice with either the
Nipah virus isolate from Bangladesh or Malaysia resulted in asymptomatic, transient
infection of the lungs.48 Although viral RNA was detected in the lungs at 21 days
postinoculation, pulmonary lesions did not develop. Additionally, neither lesions nor
viral RNA were present in the brain and viremia was not detected. A second mouse
model that mimicked some aspects of respiratory damage reported in humans has been
developed. In this model, human lung xenografts were subcutaneously transplanted into
NSG mice, then the Malaysia Nipah virus isolate was directly injected into the
xenografts.145 The human lung xenografts developed endothelial and bronchial and
alveolar epithelial syncytia, vascular fibrinoid change and pulmonary necrosis
accompanied by hemorrhage; pulmonary inflammation was minimal. High viral titers
were present in the human lung and viremia was noted in the mice. Despite the viremia,
lesions were not detected outside the human lung xenografts and mice did not exhibit any
clinical signs. While the human lung xenograft model in NSG mice only demonstrates
some features of human Nipah virus infection, an IFNAR knockout mouse model
develops vascular, nervous system and respiratory system lesions. Inoculation of IFNAR
knockout mice with Nipah virus by either an intranasal, intraperitoneal or intracerebral
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route caused weight loss and neurologic disease.45 The intraperitoneal and intracerebral
inoculation routes were uniformly lethal, while intranasal inoculation with the same dose
was fatal in 60% of animals. Histologically, all inoculation routes were able to cause
meningoencephalitis, widespread vasculitis and necrotizing alveolitis. Unfortunately, this
animal model did not exhibit lymphoid organ lesions, which have been reported in some
fatal human Nipah virus infections.

1.2.5.2 A Domestic Cat Model of Nipah Virus Infection
Experimental oral and intranasal inoculation of domestic cats with the Nipah virus
Malaysia isolate resulted in fever, tachypnea, open-mouth breathing and dyspnea.100
Histologically, there was pulmonary hemorrhage and edema, pulmonary infarcts,
tracheobronchitis and syncytia in the endothelial, alveolar epithelial and bronchiolar
epithelial cells. Vasculitis or fibrinoid change were prominent in the lungs, spleen, lymph
nodes and meninges. Necrosis was detected in lymphoid organs. Mild nonsuppurative
meningitis was observed adjacent to meningeal arteritis in one cat. Nipah virus antigen
was identified, by immunohistochemistry, in the lung, trachea, meningeal endothelium
and spleen. Although the cat model replicates the severe respiratory clinical disease and
pulmonary, vascular and lymphoid lesions seen in some Nipah virus infected humans,
encephalitis and neurological clinical signs, which are common in humans infected with
Nipah virus, were not detected in the cat model.
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1.2.5.3 A Chicken Embryo Model of Nipah Virus Infection
Injection of the Nipah virus Malaysia isolate into the allantoic cavity or yolk sac
of chicken embryos resulted in severe, often lethal, central nervous system lesions and
multisystemic vascular disease.140 Histologically, Nipah virus antigen colocalized with
lesions. Unfortunately, clinical disease cannot be evaluated in chicken embryos and
pulmonary disease was absent in this model.

1.2.5.4 A Guinea Pig Model of Nipah Virus Infection
Intraperitoneal inoculation of guinea pigs with the Nipah virus Malaysia isolate
has caused varying degrees of disease. In one experiment, inoculated guinea pigs
developed severe vascular and nervous system disease that was fatal in approximately
93% (26 out of 28) of the animals, while a much smaller pilot study reported transient
fever and weight loss in two inoculated guinea pigs.142,156 In the study by Torres-Velez et
al, the most prominent lesions were vasculitis and fibrinoid change in all affected
tissues.142 Similar to humans, guinea pigs also developed meningitis or
meningoencephalitis and lymphoid depletion and necrosis in the spleen.142 However, only
50% of guinea pigs displayed brain lesions. In addition, only 1 of 22 guinea pigs
developed pulmonary lesions, indicating that guinea pigs are not a reliable model of
Nipah virus respiratory disease.142 Moreover, there was a unique predilection for vascular
damage in the urinary bladder and reproductive organs of guinea pigs, which has not
been reported in fatal human cases of Nipah virus infection.
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Individually, the mouse, cat, chicken embryo and guinea pig models of Nipah
virus infection only exhibit some facets of human Nipah virus disease. In contrast, the
Syrian hamster, ferret and African green monkey models of Nipah virus infection
recapitulate the respiratory and neurologic disease, vasculotropism and lymphoid organ
damage described in infected humans.

1.2.5.5 A Ferret Model of Nipah Virus Infection
Ferrets oronasally inoculated with either the Bangladesh or Malaysia isolates of
Nipah virus developed severe neurologic and/or respiratory disease.30 Clinical signs
included fever, dyspnea, ataxia, limb paralysis and facial or limb tremors. Histologically,
there was necrotizing bronchoalveolitis, lymphadenitis and rhinitis, widespread vasculitis
and meningitis. Despite the prominent neurological clinical signs, encephalitis was not
detected in any of the ferrets. Immunohistochemistry identified viral antigen in the
respiratory system, vasculature, including vessels in the brain, and lymphoid organs.
Blood and essentially all tissues examined contained viral RNA, indicating systemic
distribution of the virus. Although, the respiratory, lymphoid and nervous systems were
affected in ferrets, a major limitation of this model was the absence of encephalitis in all
animals.

1.2.5.6 An African Green Monkey Model of Nipah Virus Infection
Intratracheal inoculation of African green monkeys with the Malaysian isolate of
Nipah virus resulted in severe, often lethal disease affecting the respiratory and central
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nervous systems and vasculature.58,79 Clinical signs included tachypnea, dyspnea, openmouth breathing, fever, tachycardia, weight loss, hypotension and tremors.58,79
Radiographs showed evidence of pleural effusion in most of the primates that exhibited
open-mouth breathing, and pneumonia or pulmonary congestion.58 Severe respiratory
distress was observed in most fatal cases.79 Similar to some Nipah virus infected
humans, thrombocytopenia and hyperglycemia were observed in a few monkeys.58,79 At
necropsy, varying numbers of animals exhibited frothy fluid exuding from their nose and
mouth, pulmonary edema and congestion, urinary bladder mucosal hemorrhages and
meningeal congestion.58 Histologically, there was multiorgan vasculitis with endothelial
syncytia or fibrin thrombi.79 Infarcts were detected adjacent to fibrin thrombi.79
Interstitial pneumonia, meningoencephalitis and necrohemorrhagic splenitis and
lymphadenitis coincided with the presence of viral antigen, as detected by
immunohistochemistry.79 Viremia was detected in multiple monkeys and viral RNA was
found in essentially every organ system.58 Although the African green monkey model
recapitulated the disease observed in human cases of Nipah virus infection, African green
monkeys can be difficult to handle in BSL-4 laboratories, which are required for working
with Nipah virus, and there are ethical issues that arise when primates are used for
research.

1.2.5.7 A Syrian Hamster Model of Nipah Virus Infection
Similar to African green monkeys, Syrian hamsters emulated human Nipah virus
infections. Several laboratories have documented experimental infection of Syrian
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hamsters with either the Bangladesh or the Malaysia isolate of Nipah virus.40,42,44,107,130,156
Similar clinical signs and lesions have been reported for either intraperitoneal or
intranasal inoculation.156 Hamsters exhibited respiratory clinical signs such as labored
abdominal breathing and neurologic disease, including seizures, limb paralysis, muscle
twitching and ataxia.44,156 Inoculation with a high viral dose may result in both respiratory
and neurologic clinical signs, or solely respiratory disease, while lower viral doses
typically only cause neurologic disease.44,130 Infected hamsters developed
bronchointerstitial pneumonia, multiorgan vasculitis with endothelial syncytia and
fibrinoid change, rhinitis, meningitis or meningoencephalitis with infarcts and rare foci of
splenic necrosis.40,42,107,156 Immunohistochemistry and in situ hybridization have been
used to detect viral antigen and RNA, respectively, in the lung, brain and spleen.156
Syrian hamsters have been used to model the pathogenesis of Nipah virus infection, they
have also been integral in showing that Nipah virus can be shed in nasal and
oropharyngeal secretions and could be transmitted by direct contact, ingestion of Nipah
virus in artificial date palm sap, or potentially be transmitted by fomites.40,42 Although
both the Syrian hamster and African green monkey models of Nipah virus recapitulate
the clinical presentation and histologic lesions documented in humans, the Syrian hamster
has the added benefits of being easy to obtain, being easy to handle in BSL4 laboratories
and there are fewer ethical objections to its use in research, as compared to primates.
Thus, the Syrian hamster model was chosen to study the respiratory tract pathology and
early pathogenesis of the Malaysia and Bangladesh isolates of Nipah virus, which are
discussed in Chapters 2 and 3.
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1.2.6

A Second RNA Virus Emerges in Humans

Less than 15 years after the emergence of Nipah virus in Malaysia, a case of
pneumonia caused by a novel RNA virus was diagnosed in a man in Saudi Arabia. That
emergent respiratory virus was isolated, classified as a lineage C betacoronavirus and
eventually called the Middle East respiratory syndrome coronavirus. Details of the rise of
this novel respiratory disease will be discussed forthwith.

1.3

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

1.3.1

The Emergence of MERS-CoV

Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated
from a man with fatal pneumonia in 2012; since then the virus has infected individuals in
25 countries, including the United States.154,167 (Figure 1.3) In some countries, only
individual cases have been reported, while in other locations cluster outbreaks have
developed. The majority of affected individuals have resided in, or recently traveled to,
the Middle East. Most recently, a Korean national traveled to the Middle East and upon
return to Korea developed clinical disease and was diagnosed with MERS.153
Subsequently, there have been almost daily increases in the number of human MERSCoV infections in the Republic of Korea; more than 180 laboratory confirmed human
MERS-CoV cases have been detected and linked to healthcare settings.152 Worldwide,
more than 1300 cases of human MERS-CoV infection have been identified and more
than 900 of these cases have been reported in the Kingdom of Saudi Arabia alone.152,154
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1.3.2

Human MERS-CoV Infections

Although the first identified case of MERS-CoV infection in a human resulted in
fatal pneumonia, subsequent cases have shown that MERS-CoV can cause a wide
spectrum of disease severity, ranging from asymptomatic to fatal, fulminant respiratory
disease.95,113,114 The incubation period has been estimated to range from approximately 2
to 15 days, with a median incubation period of 5 days.11 Fever and respiratory symptoms,
such as coughing, dyspnea, rhinorrhea and sore throat are often the presenting
complaints.113,114 Respiratory disease has typically been accompanied by pulmonary
infiltrates, as observed by computed tomography (CT) or radiographs.11,63 Neutrophils
and increased numbers of macrophages have been detected by cytology on
bronchoalveolar lavage samples.63 Some patients also exhibited myalgia, fatigue,
hemoptysis, diarrhea or abdominal pain.94,113 Lymphopenia, neutrophilia and/or
thrombocytopenia are often detected on complete blood counts.63,114,167 Serum
biochemistry panels from some patients have displayed increased alanine transaminase,
lactate dehydrogenase and creatinine, suggesting liver and renal damage have
developed.11,114 Acute respiratory distress syndrome, acute renal failure, multiorgan
failure or shock have occurred late in the disease course in some patients.63,114 Median
time from symptom onset to development of severe disease has been reported to be 5
days, while progression from symptom onset to death took on average 11 days.11
Currently, the overall case fatality rate is approximately 36%.152 Comorbidities, including
cardiac or renal dysfunction, hypertension, obesity, smoking, diabetes mellitus,
immunosuppressive diseases or cancer have been detected in many of the individuals that
developed severe disease.63,95,113,114 Asymptomatic or mild, self-limiting cases have
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typically been reported in immunocompetent, previously healthy individuals.138
Originally, the vast majority of MERS-CoV cases were diagnosed in middle-aged
males.11,113 However, overall, males now make up only about 66% of reported cases and
MERS-CoV infections have been identified in all age groups, ranging from infants to the
elderly.154

1.3.3

MERS-CoV Transmission

Although the exact route of MERS-CoV transmission to humans has not been
determined, it is suspected that the virus has been zoonotically transmitted from bats to
humans, or from bats to camels to humans. (Figure 1.4) Evidence suggests that bats may
serve as a reservoir for MERS-CoV and/or its viral ancestor. Lineage C
betacoronaviruses that are phylogenetically similar to MERS-CoV in humans and camels
have been detected in multiple bat species.9,78,84,146,163 Additionally, 100% sequence
homology was detected for a 200 nucleotide fragment of the RNA-dependent RNA
polymerase of the original human MERS-CoV isolate and a virus isolate collected from a
bat in Bisha, Saudi Arabia near the home of the man from which the first isolate of
MERS-CoV was detected.96 Although PCR results from bats indicate that bats could
serve as a source of MERS-CoV infection for humans, contact between bats and humans
is limited. Additionally, the development of several, geographically separated cluster
outbreaks of MERS-CoV infections in humans indicates that zoonotic transmission to
humans has likely occurred on multiple occasions, suggesting that another animal species
in more frequent contact with humans may act as an intermediate host.35,36 Dromedary
camels have been implicated as a potential reservoir and intermediate host for MERS-
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CoV and are common in Middle Eastern countries that have reported high numbers of
human MERS-CoV infections.61
Dromedary camels are thought to harbor MERS-CoV. MERS-CoV specific
neutralizing antibodies have been detected in the serum of a high percentage of
dromedary camels in several countries, including the United Arab Emirates and Saudi
Arabia which are countries that have also reported high numbers of human MERS-CoV
infections.6,71,72,98,112,119,128 Serological evidence indicates that MERS-CoV or a MERSCoV-like virus has been infecting camels for approximately the last 30 years.105 In
addition, MERS-CoV RNA and infectious virus have been isolated from dromedary
camels.5,12,23,65,166 Camels appear to be infected with MERS-CoV early in life.5,6 Camels
are permissive to experimental MERS-CoV infection; MERS-CoV inoculated camels
exhibit mild upper respiratory tract disease with mild to moderate inflammatory lesions in
the nasal cavity, trachea, bronchi and bronchioles.2 MERS-CoV infections in camels
appear to be transient and either asymptomatic or result in mild respiratory disease, such
as rhinorrhea.2,12 It is suspected that virus transmission between camels and humans may
occur through close contact with camel respiratory secretions; high viral loads have been
detected in nasal discharge and conjunctival and nasal swabs from camels.2,112 Multiple
individuals diagnosed with MERS-CoV have reported contact with camels prior to onset
of their symptoms.95,121 In fact, on multiple camel farms MERS-CoV RNA has been
detected in nasal swabs collected from camels exhibiting respiratory disease and from
humans caring for the ill camels.12,94 Phylogenetic analysis of viral genomes from
affected humans and their camels showed the virus isolates were either identical or
exhibited minimal genetic heterogeneity, suggesting that virus transmission had occurred
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between these two species.12,65,94 In these cases, zoonotic transmission was thought to
have occurred through close contact with infected camels and their respiratory
secretions.12,94 Although respiratory transmission may play a major role in zoonotic
transmission of this virus, foodborne transmission through ingestion of raw camel milk
containing MERS-CoV has not been ruled out. MERS-CoV RNA has been detected in
milk from camels.127 Additionally, infectious MERS-CoV has been shown to be stable
for a prolonged time period in refrigerated unpasteurized camel milk.148 In the Middle
East, consumption of raw camel milk is not uncommon and some individuals have
reported ingesting unpasteurized camel milk prior to contracting MERS-CoV.121
Interestingly, although seroprevalence studies have suggested that MERS-CoV infections
are a common, widespread problem in populations of dromedary camels in Africa and the
Middle East, some countries with MERS-CoV infected dromedary camels have yet to
report human MERS-CoV infections, suggesting that camel to human transmission is
limited.34,70,105,128
In addition to the proposed zoonotic transmission of MERS-CoV, human-tohuman transmission has been documented, although tends to be infrequent, with the
exception of the recently described outbreak in the Republic of Korea where human-tohuman transmission has resulted in numerous cases. Incidences of MERS-CoV
transmission among family members have been reported.47,97,114,138 Additionally,
nosocomial transmission between patients and from patients to visitors or health care
personnel has been documented frequently.4,11,63,73,91,113 In fact, in some outbreak clusters
health care personnel have made up the majority of laboratory confirmed MERS-CoV
cases.113
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1.3.4

The Pathology of MERS-CoV (and SARS-CoV) in Humans

Although over 400 human MERS-CoV infections have been fatal to date, published
autopsy results are not yet available.152 This is in part due to cultural and religious
practices in the geographic regions where most MERS-CoV infections have occurred.
Therefore, the histologic lesions caused by MERS-CoV infections in humans have yet to
be characterized. However, MERS-CoV cases have many clinical features in common
with infections caused by severe acute respiratory syndrome coronavirus (SARS-CoV).
SARS-CoV, which emerged in 2002 in China and caused outbreaks in several countries
in 2003, is a betacoronavirus related to MERS-CoV.131,151 Similar to MERS-CoV, SARSCoV caused fever and respiratory disease, often resulting in acute respiratory distress
syndrome, with some individuals also exhibiting gastrointestinal distress and
myalgia.85,118 Thoracic imaging (radiographs or CT), hematology, and serum
biochemistry results of MERS-CoV can be indistinguishable from those of SARS-CoV.85
As for MERS-CoV, SARS-CoV was thought to be transmitted from a primary animal
reservoir, likely horseshoe bats, to an intermediate animal host, civet cats, and then
transmitted to humans.57,62,143 Subsequent human-to-human and nosocomial transmission
was documented for SARS-CoV, with many cases involving healthcare workers.85
Although the overall case fatality rate for SARS-CoV was only around 10%, gross and
histologic lesions were characterized for this disease using autopsy and pulmonary biopsy
specimens.111,151 Because of the similarities, it is suspected that fatal human MERS-CoV
cases will have lesions comparable to those described for SARS-CoV. In humans
infected with SARS-CoV, pulmonary consolidation was noted at autopsy.85
Histologically, the lungs had diffuse alveolar damage with hyaline membranes,
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desquamation of pneumocytes and alveolar and interstitial inflammation.85,111
Multifocally, pneumocytes were multinucleated and vacuolated or exhibited cytomegaly
and had abundant amphophilic, granular cytoplasm.85,111 Fibrin thrombi, bronchial
epithelial erosions and bronchiolitis obliterans were also observed.111 Histologic features
similar to those described for SARS-CoV infections develop in animal models of MERSCoV. Even though MERS-CoV and SARS-CoV bind different receptors, the expression
pattern for the MERS-CoV receptor coincides with the distribution of lesions in human
SARS-CoV infections.

1.3.5

Tissue Tropism and Host Range of MERS-CoV

The receptor for MERS-CoV is dipeptidyl peptidase 4 (DPP4), also known as
CD26.125 DPP4 is a conserved type II transmembrane glycoprotein expressed by
bronchial and bronchiolar respiratory epithelium, pulmonary endothelium and vascular
smooth muscle, alveolar macrophages and type I and type II pneumocytes in multiple
species.43,52,125,149 The receptor-binding domain of the MERS-CoV spike protein (S) is
responsible for binding of the virus to DPP4 on the host cell membrane.150 The amino
acid sequence of DPP4 restricts the host range of MERS-CoV; 14 amino acids in DPP4
appear to be critical in determining whether MERS-CoV S can bind to DPP4.137,150
Human, camel, and bat DPP4 can bind MERS-CoV S, whereas multiple laboratory
animal species often used to model viral infections have significant differences in the
amino acid structure of their DPP4 binding region, which prevents MERS-CoV from
binding and entering host cells.13,149 Wildtype mice, ferrets and Syrian hamsters are
resistant to experimental MERS-CoV infections.32,33,41,126 In contrast, rhesus macaques
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and common marmosets are permissive to MERS-CoV infections and the region of DPP4
that binds MERS-CoV in these nonhuman primate species is identical to that in
humans.43,52,149 As there are still many gaps in our knowledge of human MERS-CoV
infections, the development of animal models for this recently emerged respiratory
disease is of utmost importance.

1.3.6

Animal Models of MERS-CoV Infection

Although most laboratory rodents were resistant to MERS-CoV infection, several
animal species were permissive, including New Zealand white rabbits, rhesus macaques
and common marmosets.43,52,66,106 In addition, human DPP4 expressing transduced and
transgenic mice permissive to MERS-CoV infection have been developed.3,168 The extent
to which each of these species developed clinical disease and lesions varied. New
Zealand white rabbits inoculated with MERS-CoV were asymptomatic, yet developed
mild upper and lower respiratory tract lesions and infectious virus could be isolated from
their lungs.66 Human DPP4 transduced mice exhibited minor weight loss or lack of
weight gain, mild pulmonary congestion and interstitial pneumonia; however, disease and
human DPP4 expression were both transient.168 In human DPP4 transgenic mice, severe
respiratory disease developed, which was 100% fatal; pulmonary consolidation was seen
grossly and bronchointerstitial pneumonia was observed microscopically.3 Fever and
mild to moderate respiratory disease accompanied by bronchointerstitial pneumonia with
hyaline membranes were observed in rhesus macaques.43,106 Common marmosets
exhibited severe respiratory disease and widespread bronchointerstitial pneumonia with
hyaline membranes and bronchial erosions.52 An overview of all available animal models
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of MERS-CoV infection is available in Chapter 4 and an in depth comparison of the
respiratory tract pathology and pathogenesis of MERS-CoV in the rhesus macaque and
common marmoset models can be found in Chapter 5.

1.4

Conclusion and Hypotheses

Multiple emerging viral infections that cause human respiratory disease have been
discovered within the last 15 years. Many of these emerging infectious diseases have
been transmitted from a wildlife reservoir to humans, making it difficult to control or
prevent human disease. As the number of reported emerging infectious disease outbreaks
has steadily increased since the 1940’s, development of animal models is vital for
determining the pathogenesis of these emerging pathogens. A better understanding of the
pathogenesis combined with the availability of robust animal models enables
development and efficacy testing of antivirals and vaccines. The research presented here
was undertaken to improve our understanding of the respiratory tract pathology and
pathogenesis of two emergent viral infections.
We first set out to elucidate whether a Nipah virus isolate from Bangladesh (NiVB) and a Nipah virus isolate from Malaysia (NiV-M) caused comparable late stage
respiratory tract lesions in a Syrian hamster model. We hypothesized that “NiV-B would
cause more severe late stage respiratory pathology than NiV-M, due to the higher case
fatality rate and prevalence of respiratory disease reported in humans in the Bangladesh
outbreaks, as compared to the Malaysia outbreak.” In addition to understanding the late
stages of Nipah virus disease, we also wanted to identify the target organ systems and cell
types for NiV-B and NiV-M during early infection, so the dissemination of the virus from
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its initial target cells to end-stage disease could be mapped. Based on epidemiologic data
from human outbreaks and information on the late stages of disease in animal models of
Nipah virus, we hypothesized that “Nipah virus binding and replication for both NiV-B
and NiV-M would first occur in the respiratory and olfactory epithelium in the nasal
cavity and in the pulmonary pneumocytes.”
For MERS-CoV, we evaluated available animal models of MERS-CoV infection
in regard to their ability to recapitulate the clinical presentations observed in human
MERS-CoV cases and their development of respiratory tract pathology. Then we
compared the respiratory tract pathology and pathogenesis of MERS-CoV in two recently
developed nonhuman primate models. We hypothesized that “the increased clinical
disease severity reported in the common marmoset model of MERS-CoV, as compared to
the rhesus macaque model, was caused by increased virus replication in the lungs and
development of more extensive pulmonary lesions.”
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Figure 1.1 Geographic distribution of human Nipah virus outbreaks. Countries where
outbreaks have occurred are shown in tan. Numbers indicate the cumulative number of
human Nipah virus infections reported per country, to date.
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Figure 1.2 Proposed transmission cycles for Nipah virus in the outbreaks in Malaysia (A)
and Bangladesh (B). A. In Malaysia, Nipah virus was likely transmitted from flying
foxes, which serve as a reservoir for Nipah virus, to pigs, through ingestion of partially
eaten mangos that were contaminated with flying fox saliva or urine that contained Nipah
virus. Nipah virus then rapidly spread among pigs, likely through contact with Nipah
virus infected pig oral or respiratory secretions or urine. Transmission of Nipah virus
from pigs to humans was most likely caused by humans coming into direct contact with
Nipah virus infected pigs and their secretions. Human-to-human transmission was not
detected in the Nipah virus outbreak in Malaysia. B. In Bangladesh, Nipah virus was
thought to have been transmitted from flying foxes to humans, by humans ingesting date
palm sap contaminated with flying fox urine or saliva that contained Nipah virus. The
contamination of date palm sap likely occurred when flying foxes were feeding from the
pots that were collecting date palm sap. Subsequently, human-to-human transmission of
Nipah virus was reported, this was thought to occur through close contact with
respiratory tract secretions containing Nipah virus.
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Figure 1.3 Geographic distribution of Middle East respiratory syndrome coronavirus
(MERS-CoV) infections in humans. Countries where human MERS-CoV infections have
been identified are shown in tan. Numbers indicate the cumulative number of human
MERS-CoV infections reported per country, to date.
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Figure 1.4 Proposed transmission cycles for MERS-CoV. It is thought that MERS-CoV
is transmitted either from bats to humans, although contact between these species is often
limited, or from bats to dromedary camels to humans. Transmission between dromedary
camels and humans may occur when humans come into close contact with infected camel
respiratory tract secretions or through ingestion of unpasteurized camel milk containing
MERS-CoV. Human-to-human transmission likely occurs through close contact with
human respiratory tract secretions containing MERS-CoV.
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2.1

Abstract

Nipah virus is a paramyxovirus in the genus Henipavirus, which has caused
outbreaks in humans in Malaysia, India, Singapore and Bangladesh. Whereas the human
cases in Malaysia were characterized mainly by neurological symptoms and a case
fatality rate of ~40%, cases in Bangladesh also exhibited respiratory disease and had a
case fatality rate of ~70%. Here, we compared the histopathologic changes in the
respiratory tract of Syrian hamsters, a well-established small animal disease model for
Nipah virus, inoculated oronasally with Nipah virus isolates from human cases in
Malaysia and Bangladesh. The Nipah virus isolate from Bangladesh caused slightly more
severe rhinitis and bronchointerstitial pneumonia 2 days after inoculation in Syrian
hamsters. By day 4, differences in lesion severity could no longer be detected.
Immunohistochemistry demonstrated Nipah virus antigen in nasal cavity and pulmonary
lesions; the amount of Nipah virus antigen present correlated with lesion severity.
Immunohistochemistry indicated that both Nipah virus isolates exhibited
endotheliotropism in small- and medium-caliber arteries and arterioles, but not in veins,
in the lung. This correlated with the location of ephrin B2, the main receptor for Nipah
virus, in the vasculature. In conclusion, Nipah virus isolates from outbreaks in Malaysia
and Bangladesh caused a similar type and severity of respiratory tract lesions in Syrian
hamsters, suggesting that the differences in human disease reported in the outbreaks in
Malaysia and Bangladesh are unlikely to have been caused by intrinsic differences in
these 2 virus isolates.

51
2.2

Introduction

Nipah virus is a paramyxovirus in the genus Henipavirus. Nipah virus was first
identified in an outbreak in 1998 to 1999 in Malaysia, where it caused encephalitis and
respiratory signs in pigs and encephalitis in humans who had contact with infected pigs.3,5
Since 2001, Nipah virus has caused outbreaks in humans in Bangladesh almost every
year. Whereas the initial outbreak in humans in Malaysia and Singapore was
characterized mainly by neurological symptoms with occasional respiratory symptoms
and a case fatality rate of approximately 40%,3 human cases in Bangladesh exhibited
respiratory as well as neurological disease with a case fatality rate up to 92% in
individual outbreaks.15 The main histologic changes in humans infected with Nipah virus
in Malaysia were multiorgan vasculitis, fibrin thrombi, fibrinoid necrosis and occasional
endothelial syncytia; vascular lesions were often associated with parenchymal necrosis
and hemorrhage, especially in the brain with lesser involvement of the lung.20 In the
Malaysia outbreak, Nipah virus was transmitted from its natural reservoir, Pteropus spp
fruit bats, to pigs. It is suspected that pigs were infected by ingesting fruit contaminated
with urine, feces or saliva from Nipah virus-infected fruit bats.14 Pigs acted as an
intermediate, amplifying host for Nipah virus and transmitted this virus to humans
through direct contact.4,16 Histologic lesions in Nipah virus-infected individuals from
Bangladesh have not been described; however, the Bangladesh isolate has been reported
to cause clinical symptoms similar to those in the Malaysia outbreak with the addition of
acute respiratory distress syndrome.13 In the outbreaks in Bangladesh, epidemiologic
studies suggest that Nipah virus was transmitted from fruit bats to humans through
ingestion of raw date palm sap contaminated with Nipah virus through bat saliva, urine or
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feces.15 Infected humans then transmitted the virus to other humans, likely through close
contact with respiratory tract secretions.11 Nipah virus isolates from Malaysia and
Bangladesh have been shown to share a sequence identity of 91.8% on the nucleotide
level and >92% on the amino acid level.12
Comparisons of a Nipah virus isolate from Malaysia to a Nipah virus isolate from
Bangladesh in oronasally inoculated ferrets and intraperitoneally inoculated hamsters
have been reported. Clayton et al6 showed that ferrets inoculated oronasally with either
Nipah virus isolate developed similar clinical signs and multisystemic inflammation with
vasculitis, yet ferrets inoculated with the Nipah virus isolate from Malaysia occasionally
developed meningitis, while those inoculated with the Bangladesh isolate did not.
Intraperitoneal inoculation of Syrian hamsters with either the Nipah virus isolate from
Malaysia or Bangladesh resulted in similar histologic lesions, although the lesions
developed more rapidly in hamsters inoculated with the Nipah virus isolate from
Malaysia.9
Here, we compare histologic lesions in the respiratory tract of Syrian hamsters
oronasally inoculated with 107 TCID50 (50% tissue culture infectious dose) of a Nipah
virus isolate from Malaysia (NiV-M) or Bangladesh (NiV-B). Although a previous study
compared lesions caused by intraperitoneal inoculation of NiV-M or NiV-B in hamsters,
this inoculation route may not accurately represent natural disease progression in humans.
In our study comparing oronasally inoculated hamsters, differences in the severity of
respiratory tract lesions in hamsters caused by NiV-B and NiV-M were minimal and only
noted at 2 days post inoculation (dpi), with NiV-B causing slightly more severe lesions.
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2.3

Materials and Methods

2.3.1

Ethics Statement

All animal experiments were approved by the Institutional Animal Care and Use
Committee of the Rocky Mountain Laboratories and performed following the guidelines
of the Association for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) by certified staff in an AAALAC-approved facility.

2.3.2

Case Selection and Histology

Archived microscope slides from 6- to 8-week-old female Syrian hamsters
(HsdHan:AURA; Harlan Laboratories, Indianapolis, Indiana), from previously published
studies,7,8 euthanized 2 or 4 days after oronasal inoculation with 107 TCID50 NiV-M or
NiV-B in a total volume of 100 µl or 80 µl respectively (50 or 40 µl/nostril) were
analyzed histologically. Slides were originally prepared as 5-µm-thick sections of
formalin-fixed, paraffin-embedded tissues adhered to microscope slides and then stained
with hematoxylin and eosin or Verhoeff-Van Gieson stain. The Nipah virus isolates from
Malaysia and Bangladesh were kindly provided by the Special Pathogens Branch of the
Centers for Disease Control and Prevention (Atlanta, GA). NiV-M was isolated from the
cerebrum of an infected fatal human case in 1999. NiV-B was isolated from a throat swab
collected from a fatal human case in 2004.
In the archived Nipah virus microscope slides, 5 hamsters inoculated were
inoculated with NiV-M; 3 of these hamsters were euthanized at 2 dpi (case Nos. 1M-3M)
and 2 hamsters (case Nos. 4M, 5M) were euthanized at 4 dpi. Eight hamsters were
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inoculated with NiV-B; 4 hamsters each were euthanized at 2 dpi (case Nos. 6B-9B) and
4 dpi (case Nos. 10B-13B). Examined tissues included the lung, nasal cavity (transverse
or mid-sagittal sections through the skull) and brain. All tissues were analyzed for the
presence of lesions and scored in a non-masked manner by two pathologists (L.B.,
D.P.S.). Any discrepancies in scoring values were discussed and a final score was
mutually agreed on by the pathologists. Lesion severity was scored as follows: 0 = the
lesion was absent, 1 = up to 25% of the described tissue or cell type was affected, 2 = up
to 50% of the described tissue or cell type was affected, 3 = up to 75% of the described
tissue or cell type was affected, and 4 = 75% to 100% of the described tissue or cell type
was affected.

2.3.3

Immunohistochemistry

Immunohistochemistry was performed on all tissues examined histologically
using a rabbit polyclonal antiserum against the Nipah virus nucleoprotein2 (1:5000;
kindly provided by L. Wang, CSIRO Livestock Industries, Australian Animal Health
Laboratory, Geelong, Victoria, Australia) as a primary antibody for detection of Nipah
virus antigen. The tissues were then processed for immunohistochemistry using the
Discovery XT automated processor (Ventana Medical Systems, Tucson, AZ) with a DAB
Map kit (Ventana Medical Systems). All tissues were scored based on the percentage of
the tissue that was immunopositive for Nipah virus nucleoprotein: 0 = negative, 1 = up to
25% of the tissue was immunopositive, 2 = up to 50% of the tissue was immunopositive,
3 = up to 75% of the tissue was immunopositive, 4 = 75% to 100% of the tissue was
immunopositive. Scoring was performed in a non-masked manner by two pathologists
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(L.B., D.P.S.); any discrepancies in scoring values were discussed and a final score was
mutually agreed upon by the pathologists.

2.3.4

Statistical Analysis

A Fisher’s exact test was performed using GraphPad (Prism version 6.02 for
Windows, GraphPad Software, La Jolla, CA) to determine statistical significance
between the scoring values of animals inoculated with NiV-B or NiV-M at each time
point and for the presence or absence of Nipah virus nucleoprotein in arteries or veins in
the lung. P < .05 was considered statistically significant.

2.4

2.4.1

Results

Nasal Cavity

In the nasal cavity, the histologic differences between hamsters inoculated with
NiV-B and NiV-M were minimal and observed on day 2 only (Table 2.1). Differences in
lesion severity were seen in the submucosal glands and respiratory and olfactory
epithelium. Submucosal gland epithelial degeneration on 2 dpi was present only in
hamsters inoculated with NiV-B. NiV-B caused slightly more severe olfactory epithelial
lesions than NiV-M 2 dpi, whereas NiV-M caused slightly more severe respiratory
epithelial lesions. Both Nipah virus isolates caused mild neutrophilic rhinitis with
respiratory and olfactory epithelial degeneration, necrosis and syncytia formation (Figure
2.1 A, B). Rhinitis caused by NiV-B was multifocal to coalescing and affected up to 10%
of the nasal cavity, whereas rhinitis produced by NiV-M was often focal and affected 5%
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or less of the nasal cavity. Nasal cavity lesions were more severe at 4 dpi than at 2 dpi for
both NiV-B and NiV-M. Lesion severity and distribution were similar at 4 dpi for both
virus isolates (Figure 2.1 C, D; Table 2.2), with up to 50% of the nasal cavity being filled
with inflammatory infiltrate. Multifocal to coalescing ulcers and submucosal gland
epithelial degeneration, necrosis and syncytia were present. Prominent vascular lesions
were observed at 4 dpi, including fibrinoid degeneration and fibrin thrombi in multiple
nasal submucosal small- and medium-caliber vessels.
Nipah virus antigen was detected in the same cell types in hamsters inoculated
with either NiV-M or NiV-B and antigen was more abundant at 4 dpi compared to 2 dpi
(Table 2.3). Multifocally, Nipah virus antigen was present in the cytoplasm of nasal
cavity olfactory, respiratory and submucosal gland acinar epithelium, mononuclear
leukocytes and neutrophils (Figure 2.2 A-D). Nipah virus antigen was also present in the
cytoplasm of endothelial cells in small- to medium-caliber vessels in the nasal submucosa
in all hamsters inoculated with NiV-M at 4 dpi, but was not present at 2 dpi. In hamsters
inoculated with NiV-B, 1 out of 4 hamsters (25%) at 2 dpi and 3 out of 4 hamsters (75%)
at 4 dpi expressed Nipah virus antigen in endothelial cells.
The only statistically significant difference (P < .03) between NiV-M and NiV-B
in the nasal cavity was the presence of submucosal gland epithelial degeneration in
hamsters inoculated with NiV-B, but not NiV-M, at 2 dpi, as determined by a Fisher’s
exact test.
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2.4.2

Lung

Differences in lesion severity caused by NiV-B and NiV-M were minor and noted
only at 2 dpi, and involved the extent of the bronchointerstitial pneumonia (Table 2.1)
and formation of bronchiolar epithelial syncytia. Both Nipah virus isolates caused a
multifocally distributed bronchointerstitial pneumonia centered on terminal bronchioles
with scattered fibrin thrombi in alveolar septal capillaries in all hamsters at 2 dpi. NiV-B
caused more extensive bronchointerstitial pneumonia at 2 dpi than NiV-M, affecting up
to 50% of the lung as compared with less than 25% of the lung, respectively (Figure 2.3
A, B). Multiple small- and medium-caliber blood vessels in the lung exhibited vasculitis
with disruption of the vascular wall and rare endothelial syncytia in hamsters inoculated
with either virus isolate. Bronchiolar epithelial syncytia were seen at 2 dpi in all hamsters
inoculated with NiV-M, but were present only in 1 of 4 hamsters inoculated with NiV-B.
At 4 dpi, bronchiolar epithelial syncytia were present in 1 of 2 hamsters inoculated with
NiV-M and 1 of 4 hamsters inoculated with NiV-B. At 4 dpi the bronchointerstitial
pneumonia caused by NiV-B and NiV-M had a similar distribution and severity (Table
2.2), was more extensive than at 2 dpi, affected up to 75% of the lung, and exhibited
multifocal type II pneumocyte hyperplasia (Figure 2.3 C, D).
In the lung, the location of Nipah virus antigen was similar for both NiV-B and
NiV-M (Figure 2.4 A-D) and the amount of antigen present for both virus isolates
increased from 2 dpi to 4 dpi (Table 2.3). Nipah virus antigen was detected in the
cytoplasm of multiple alveolar septal capillary endothelial cells, type I pneumocytes, and
mononuclear leukocytes at 2 dpi in all hamsters. Nipah virus antigen was present in
endothelium of rare small-caliber blood vessels at 2 dpi in 1 hamster inoculated with
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NiV-M (case No. 2M) and 1 hamster inoculated with NiV-B (case No. 9B). At 4 dpi,
Nipah virus antigen was also present in scattered type II pneumocytes, endothelial cells,
and vascular smooth muscle cells in hamsters inoculated with either NiV-B or NiV-M.

2.4.3

Pulmonary Vasculature

Nipah virus antigen was present in endothelial and smooth muscle cells in
multiple small- and medium-caliber blood vessels at 4 dpi in the lung of hamsters
inoculated with either NiV-B or NiV-M. Through the comparison of hematoxylin and
eosin (HE) and Nipah virus antigen immunohistochemistry on sequential sections of
lung, it appeared that Nipah virus antigen had a tropism for arteries rather than veins.
Since it can be difficult to differentiate small- and medium-caliber arteries and veins in
the lung on HE, a Verhoeff-Van Gieson stain was performed on sections of lung to
identify the presence or absence of internal and external elastic laminae in blood vessels.
A comparison of HE, Verhoeff-Van Gieson and immunohistochemistry using anti-Nipah
virus nucleoprotein antibody on serial sections of the lung was performed on all hamsters
inoculated with either NiV-B or NiV-M that were euthanized at 4 dpi to elucidate if there
was an arterial tropism. Ten arteries and ten veins were analyzed in each hamster.
Multiple small-caliber blood vessels were not included in the analysis since their scanty
tunica media made it difficult to discern if there was 1 lamina or 2 laminae that were
barely separated by a thin tunica media. In each hamster, the endothelium of at least 5 of
10 arteries examined contained Nipah virus nucleoprotein (Figure 2.5 A-C), whereas
none of the veins did (Figure 2.5 D-F). This arterial tropism was observed in hamsters
inoculated with either virus isolate and was statistically significant (P < .003) compared
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with the absence of Nipah virus nucleoprotein in venous endothelium using a Fisher’s
exact test.

2.4.4

Brain

Lesions were not present in the brain in any hamster inoculated with either Nipah
virus isolate. Nipah virus antigen was not observed in the brain parenchyma in any
hamster at either 2 dpi or 4 dpi.

2.5

Discussion

Syrian hamsters were used as an animal model to investigate histopathologic
differences between NiV-M and NiV-B since they recapitulate the disease caused by
Nipah virus in humans.7,9,17,19 In Nipah virus-infected hamsters, clinical signs and
histologic lesions depend on the infectious dose and route of inoculation. Hamsters
oronasally inoculated with a high dose of Nipah virus develop acute severe respiratory
disease, while low doses initially cause mild respiratory disease and then subsequent
neurological signs.17 High doses of NiV-B or NiV-M have both been shown to be
uniformly lethal in oronasally inoculated hamsters.7,8 In this study, all hamsters were
inoculated with a high dose of either NiV-B or NiV-M to evaluate the respiratory
component of these diseases. At the time points that were examined, Nipah virus antigen
had not yet disseminated to the brain, as determined by immunohistochemistry, and
lesions were not present in this tissue. Oronasal inoculation of hamsters with NiV-B or
NiV-M resulted in subtle differences in lesion severity in the respiratory tract at 2 dpi,
with NiV-B causing slightly more severe lesions at that time point.
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Immunohistochemistry for Nipah virus antigen in the nasal cavity 2 days after oronasal
inoculation with NiV-M or NiV-B in Syrian hamsters showed that a higher percentage of
epithelial cells in the nasal cavity contained Nipah virus antigen in hamsters inoculated
with NiV-B. Although this may have been due to the different inoculum volumes used, it
could also indicate that NiV-B entry into epithelial cells lining the nasal cavity is more
rapid than NiV-M entry into cells or that NiV-B replicates faster within epithelial cells
than NiV-M. This is one scenario that may also explain the observed lesions in the
submucosal gland epithelium in NiV-B infected hamsters on 2 dpi, as a faster replication
rate may have resulted in a faster progression to infection of this deeper-lying tissue.
On 2 dpi, NiV-B showed a slight predilection for damaging olfactory epithelium
and NiV-M exhibited a slight predilection for damaging respiratory epithelium in
oronasally infected hamsters. The exact mechanism behind these predilections is
unknown, but could possibly be due to genetic differences resulting in phenotypic
variation in the glycoproteins G and F between these two isolates12 which may affect cell
entry of these viruses through host receptor binding on olfactory or respiratory
epithelium. In addition, a combination of viral genetic differences and variations in
cellular structure and function between respiratory and olfactory epithelium may have
caused differences in the viral replication rates in these two epithelial cell types.
By 4 dpi, the type and severity of lesions in the lung and nasal cavity was similar
for both Nipah virus isolates. Although disease progression was initially more rapid for
NiV-B, by 4 dpi both Nipah virus isolates caused essentially the same severity of
pulmonary and nasal cavity lesions in Syrian hamsters. Similarly, in ferrets oronasally
inoculated with NiV-B or NiV-M, the clinical respiratory signs and respiratory tract
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histologic lesions were comparable.6 Intraperitoneal inoculation of Syrian hamsters with
NiV-B or NiV-M also did not result in differences in lesion severity between the 2
isolates, although disease onset and lesion development were faster with NiV-M than
NiV-B.9 However, all studies to date comparing NiV-M and NiV-B have used the same 2
isolates and the results would be strengthened if these studies could be repeated using
virus isolates from different outbreaks in Bangladesh.
To our knowledge, this is the first study that describes the tropism of Nipah virus
for endothelium within arteries and arterioles, but not veins. Other studies have examined
the presence of Nipah virus antigen within blood vessels, but have not exclusively
localized antigen to endothelium in arteries and arterioles rather than veins.10,20 This
tropism correlates with the expression of ephrin B2, the main receptor for Nipah virus, in
arterial but not venous endothelium; venous endothelium typically expresses Eph-B418
which is not a receptor for Nipah virus.
Taken together, the results presented here do not explain the increased case
fatality rate seen in humans infected with NiV-B; rather, the results suggest that
differences between the outbreaks in Malaysia and Bangladesh were not caused by
intrinsic differences between NiV-B and NiV-M. Other factors, such as the route of
infection or dose of the virus received, which were identical in hamsters inoculated with
either NiV-B or NiV-M in this study, may have played a role in the differences in disease
outcome in infected humans in Malaysia and Bangladesh. For instance, in the Malaysia
outbreak, humans were exposed to the virus through close contact with pigs,16 whereas in
the Bangladesh outbreaks, humans were thought to be infected by drinking Nipah viruscontaminated date palm sap or through direct contact with respiratory secretions from
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infected humans.11,15 In addition, differences in the availability of health care facilities,
willingness to seek medical care early in the infection, the role that family members play
in caring for the ill or other cultural differences may play a role in the differences noted
between the outbreaks in Malaysia and Bangladesh in humans.
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Table 2.1 Histologic severity of respiratory tract lesions in Syrian hamsters inoculated
with a Nipah virus isolate from Malaysia or Bangladesh at 2 days post inoculation.
Hamster
No./
Isolate
1M/Mal
2M/Mal
3M/Mal
6B/Bang
7B/Bang
8B/Bang
9B/Bang

Rhinitis

Respiratory Epi.
Deg./Necrosis

Olfactory Epi.
Deg./Necrosis

Submucosal Gland
Acinar Deg./ Necrosis

Bronchointerstitial
Pneumonia

1
1
1
1
1
1
1

1/1
2/0
2/2
1/0
3/1
1/0
1/0

1/1
1/1
0/0
1/1
1/1
1/1
2/1

0/0
0/0
0/0
1/0
1/0
1/0
1/0

1
1
1
2
2
1
2

Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus isolate from Bangladesh; Epi.,
Epithelial; Deg., Degeneration.
Tissues from the nasal cavity (respiratory epithelium, olfactory epithelium and
submucosal glands) and lung (bronchointerstitial pneumonia) were scored. Scoring
protocol: 0 = no lesions; 1 = up to 25% of the described tissue or cell type affected; 2 =
up to 50% of the described tissue or cell type affected; 3 = up to 75% of the described
tissue or cell type affected; 4 = 75% to 100% of the described tissue or cell type affected.
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Table 2.2 Histologic severity of respiratory tract lesions in Syrian hamsters inoculated
with a Nipah virus isolate from Malaysia or Bangladesh at 4 days post inoculation
Hamster
No./
Isolate
4M/Mal
5M/Mal
10B/Bang
11B/Bang
12B/Bang
13B/Bang

Rhinitis

Respiratory Epi.
Deg./Necrosis

Olfactory Epi.
Deg./Necrosis

Submucosal Gland
Acinar Deg./ Necrosis

Bronchointerstitial
Pneumonia

2
2
1
2
1
2

2/1
3/1
1/1
0/0
1/0
1/1

2/1
1/2
1/0
2/2
1/2
2/2

1/1
1/2
1/0
2/1
1/1
2/2

3
1
3
2
3
2

Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus isolate from Bangladesh; Epi.,
Epithelial; Deg., Degeneration.
Tissues from the nasal cavity (respiratory epithelium, olfactory epithelium and
submucosal glands) and lung (bronchointerstitial pneumonia) were scored. Scoring
protocol: 0 = no lesions; 1 = up to 25% of the described tissue or cell type affected; 2 =
up to 50% of the described tissue or cell type affected; 3 = up to 75% of the described
tissue or cell type affected; 4 = 75% to 100% of the described tissue or cell type affected.
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Table 2.3 Immunohistochemistry scoring for Nipah virus nucleoprotein in the respiratory
tract of Syrian hamsters inoculated with either a Nipah virus isolate from Malaysia or
Bangladesh
Hamster No.
1M
2M
3M
4M
5M
6B
7B
8B
9B
10B
11B
12B
13B

Isolate
Mal
Mal
Mal
Mal
Mal
Bang
Bang
Bang
Bang
Bang
Bang
Bang
Bang

Necropsy, Dpi
2
2
2
4
4
2
2
2
2
4
4
4
4

Nasal Cavity
1
1
1
2
3
2
2
2
2
1
3
2
2

Lung
2
2
2
3
1
2
3
2
2
3
3
2
2

Dpi, days post inoculation; Mal, Nipah virus isolate from Malaysia; Bang, Nipah virus
isolate from Bangladesh.
Scoring protocol: 0 = negative, 1 = up to 25% of the tissue was immunopositive; 2 = up
to 50% of the tissue was immunopositive; 3 = up to 75% of the tissue was
immunopositive; 4 = 75% to 100% of the tissue was immunopositive.
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Figure 2.1 Infection with a Nipah virus isolate from Malaysia (NiV-M) or Bangladesh
(NiV-B), Syrian hamster, nasal cavity. HE. A. Rhinitis with olfactory epithelial
degeneration and necrosis and multifocal erosions (arrows; inset) 2 days post inoculation
(dpi) with NiV-M. B. Rhinitis with olfactory epithelial degeneration and necrosis
(arrows; inset) 2 dpi with NiV-B. C. Rhinitis with multifocal ulcers (asterisk) and
submucosal vascular fibrinoid degeneration (arrow; inset) 4 dpi with NiV-M. D. Rhinitis
affecting olfactory epithelium (asterisk) and respiratory epithelium (arrowhead) with
formation of epithelial syncytium (arrow; inset) 4 dpi with NiV-B.
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Figure 2.2 Infection with a Nipah virus isolate from Malaysia (NiV-M) or Bangladesh
(NiV-B), Syrian hamster, nasal cavity. IHC for Nipah virus nucleoprotein. A.
Cytoplasmic expression of viral antigen in olfactory epithelium (arrow) 2 days post
inoculation (dpi) with NiV-M. B. Cytoplasmic expression of viral antigen in olfactory
(arrow) and submucosal gland acinar epithelium (arrowhead) 2 dpi with NiV-B. C.
Cytoplasmic expression of viral antigen in olfactory (arrow) and submucosal gland acinar
epithelium (arrowhead) 4 dpi with NiV-M. D. Cytoplasmic expression of viral antigen in
olfactory (arrow) and submucosal gland acinar epithelium (arrowhead) 4 dpi with NiV-B.

71

Figure 2.3 NiV-M or NiV-B infection, Syrian hamster, lung. HE. A. Bronchointerstitial
pneumonia with bronchiolar epithelial syncytium (arrow; inset) 2 dpi with NiV-M. B.
Bronchointerstitial pneumonia 2 dpi with NiV-B. Inset: higher magnification of
pneumonia. C. Bronchointerstitial pneumonia with type II pneumocyte hyperplasia
(arrow; inset) 4 dpi with NiV-M. D. Bronchointerstitial pneumonia with type II
pneumocyte hyperplasia (arrow; inset) 4 dpi with NiV-B.
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Figure 2.4 NiV-M or NiV-B infection, Syrian hamster, lung. IHC for Nipah virus
nucleoprotein. A. Cytoplasmic expression of viral antigen in type I pneumocytes (arrow)
and bronchiolar epithelium (arrowhead) 2 dpi with NiV-M. B. Cytoplasmic expression of
viral antigen in type I pneumocytes (arrow) 2 dpi with NiV-B. C. Cytoplasmic expression
of viral antigen in type I (black arrow) and type II pneumocytes (arrowhead) and
mononuclear leukocytes (white arrow) 4 dpi with NiV-M. D. Cytoplasmic expression of
viral antigen in type I (black arrow) and type II pneumocytes (arrowhead) and
mononuclear leukocytes (white arrow) 4 dpi with NiV-B.
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Figure 2.5 A-C. Nipah virus infection, Syrian hamster, serial sections of an artery in the
lung. A. The tunica adventitia is expanded by edema and a mild infiltrate of neutrophils,
lymphocytes and macrophages (asterisk; inset). HE. B. Cytoplasmic expression of Nipah
virus nucleoprotein in arterial endothelial cells (arrow), smooth muscle cells in the tunica
media (asterisk) and perivascular leukocytes (arrowhead). Inset: higher magnification of
viral antigen expression. Nipah virus nucleoprotein IHC. C. Internal (arrowhead) and
external (arrow) elastic laminae are prominent in this vessel, indicating the vessel is a
pulmonary artery. Inset: higher magnification of vascular elastic laminae. Verhoeff-Van
Gieson stain. D-F. Nipah virus infection, Syrian hamster, serial sections of a vein in the
lung. D. The tunica adventitia is expanded by an infiltrate of neutrophils and
macrophages with fewer lymphocytes and plasma cells (asterisk; inset). HE. E.
Cytoplasmic expression of Nipah virus nucleoprotein in perivascular leukocytes (arrow;
inset). Nipah virus antigen was not present in endothelial cells. Nipah virus nucleoprotein
IHC. F. The vessel exhibits an incomplete internal elastic lamina (arrow; high-power
inset) and lacks an external elastic lamina, indicating this vessel is a pulmonary vein.
Verhoeff-Van Gieson stain.
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3.1

Abstract

In humans, Nipah virus causes respiratory disease and neurologic symptoms. In
fatal human Nipah virus infections, lesions have been described in the respiratory and
nervous systems, vasculature and lymphoid organs; cellular damage was reported in
epithelial cells, endothelial cells and neurons. However, since the reported data are from
the late stages of disease, the progression of Nipah virus infection through the different
target organs and cells during the early phase of disease remains poorly understood. Here,
we tracked Nipah virus dissemination during the early phase of infection in intranasally
inoculated Syrian hamsters with either a Nipah virus isolate from Malaysia (NiV-M) or
Bangladesh (NiV-B). Nipah virus initially targeted the lung and nasal cavity. Virus
replication was identified at 8 hours post inoculation (hpi) in type I pneumocytes,
bronchiolar respiratory epithelium and alveolar macrophages. Viral spread to bronchiolar
smooth muscle and arterial smooth muscle in the lung was first detected at 16 hpi and 32
hpi, respectively. In the nasal cavity, respiratory and olfactory epithelium were initially
targeted, followed by spread to underlying submucosal gland acinar epithelium. Virus
appeared to spread from the lung and/or nasal cavity to the larynx and trachea. The
pattern of viral dissemination was similar in NiV-M and NiV-B inoculated hamsters;
however, dissemination was slower for NiV-B. In hamsters inoculated with either virus
isolate, even at 48 hpi we did not detect infectious virus in the central nervous system or
viral infection of blood vessels in multiple organs. These results suggest that virus
replication in the brain and viral infection of blood vessels in non-respiratory tract tissues
does not occur during the early phase of infection and may be prevented by rapid
administration of antivirals into the upper and lower respiratory tract.
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3.2

Introduction

Nipah virus is a highly virulent, zoonotic paramyxovirus that was first identified
in an outbreak that affected pigs and humans in Malaysia and Singapore in 1998-1999.5,21
Subsequently, Nipah virus has caused almost yearly outbreaks in humans in
Bangladesh.13,14,16,22 Humans infected during the initial outbreak in Malaysia mainly
exhibited neurologic symptoms while some also developed respiratory disease; the case
fatality rate was approximately 40%.4,10,20,30 Outbreaks in Bangladesh have resulted in
neurologic disease, a higher incidence of respiratory disease, limited human-to-human
transmission and case fatality rates up to 100%.12,14,24,28 Histologic lesions have only been
described in fatal human cases from the Malaysia outbreak and were characterized by
systemic vascular damage often associated with infarcts in the central nervous system and
lung.5,10,30 Tissues analyzed from fatal human Nipah virus infections depicted signs of
cellular damage in endothelial cells, neurons and epithelial cells.30 Additionally, in a few
of the fatal human cases, lesions were reported in lymphoid organs, including the spleen,
which exhibited white pulp lymphoid depletion, and lymph nodes.30 These findings show
that the vasculature and the respiratory, nervous and immune systems are infected by
Nipah virus. However, since the reported data are from the late stages of disease, the
progression of Nipah virus infection through the different target organs remains poorly
defined. Understanding the initial organ and cell types a virus targets is a vital first step
towards determining the most effective route and time frame for administering antivirals
aimed at inhibiting early virus replication and thus potentially preventing systemic virus
dissemination.
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Several animal models of Nipah virus infection have been developed, including
the Syrian hamster model which recapitulates several aspects of human Nipah virus
disease. Syrian hamsters experimentally inoculated with Nipah virus have been shown to
develop late stage lesions similar to those in humans, including vascular disease and
lesions in the respiratory and nervous systems, with rare involvement of the spleen.2,79,19,23,29

Thus, the Syrian hamster model likely mimics the early pathogenesis of Nipah

virus infection in humans and could be used to study the early target cells of Nipah virus
infection and viral spread to subsequent cells and organ systems. Although the route of
systemic virus dissemination is unclear, it is suspected that lymphocytes may play a role.
It has been shown that Nipah virus can bind to human lymphocytes and hamster
mononuclear leukocytes and that these leukocytes can carry and transfer the virus to
permissive cells.17 As such, lymphocytes may transfer virus to endothelial cells in blood
vessels throughout the body, which could cause systemic virus dissemination, potentially
followed by viral spread from blood vessels to adjacent parenchymal cells, including
epithelial cells and neurons.27 These lymphocytes can also transmigrate through vascular
walls in tissues and directly transfer Nipah virus to underlying permissive parenchymal
cells, including epithelial cells and neurons. Epithelial cells lining the respiratory tract
may not only become infected via a hematogenous route, but they can also be exposed to
Nipah virus through inhalation of viral particles. Neurons in the brain may also become
infected if Nipah virus spreads from olfactory neurons in the nasal cavity to the olfactory
nerve, which leads to the olfactory bulb of the brain.19, 27 Once in the olfactory bulb,
Nipah virus can potentially disseminate to neurons throughout the entire brain and spinal
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cord. Regardless of the route of virus dissemination, the end result is often development
of severe clinical disease and potentially death.
Here, we identified the initial target cell types and organs during the first 48 hours
of Nipah virus infection upon intranasal inoculation of Syrian hamsters. We showed that
the lung and nasal cavity are the initial target organs and that Nipah virus replication can
be identified at 8 hours post inoculation in type I pneumocytes, bronchiolar respiratory
epithelial cells and alveolar macrophages at this time point. In the nasal cavity,
respiratory and olfactory epithelium are the initial targets. Virus then appears to
disseminate to the trachea and larynx. We did not detect infectious virus or virus
replication in the central nervous system or viral infection of multisystemic blood vessels,
even at 48 hours post inoculation, suggesting these are not early events.

3.3

Materials and Methods

3.3.1

Ethics Statement

All animal experiments were approved by the Institutional Animal Care and Use
Committee of the Rocky Mountain Laboratories and performed following the guidelines
of the Association for Assessment and Accreditation of Laboratory Animal Care
International (AAALAC) by certified staff in an AAALAC-approved facility.

3.3.2

Virus and Cells

Nipah virus isolates from Bangladesh (NiV-B) and Malaysia (NiV-M) were
kindly provided by the Special Pathogens Branch of the Centers for Disease Control and
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Prevention, Atlanta, Georgia, United States. NiV-B was isolated from a throat swab
collected from a fatal human case in 2004. NiV-M was isolated from the cerebrum of a
fatal human case in 1999.

3.3.3

Animal Experiments

Two groups of twenty-four 6- to 8-week-old female Syrian hamsters
(HsdHan:AURA; Harlan Laboratories, Haslett, MI) were intranasally inoculated with 5 x
106 TCID50 (50% tissue culture infectious dose) of either NiV-B or NiV-M in a total
volume of 80 µl (40 µl per nostril). All hamsters were evaluated daily for clinical signs of
disease, including weight loss. Four hamsters from each group were euthanized at 4, 8, 16,
24, 32 and 48 hours post inoculation (hpi). A terminal heart blood sample was collected
from each hamster before necropsy. Nasal turbinates, larynx, trachea, lung, cervical
lymph nodes, spleen, brain and thoracolumbar spinal cord were collected for histologic
and virologic analysis.

3.3.4

Histology, Immunohistochemistry and In Situ Hybridization

Necropsies and tissue sampling were performed according to a standard protocol
approved by the Institutional Biosafety Committee. Tissues were fixed for a minimum of
7 days in 10% neutral-buffered formalin and embedded in paraffin. The sections of nasal
turbinates, contained within the skull, and spinal cord, contained within the vertebrae,
were decalcified using a 20% EDTA solution in sucrose prior to paraffin embedding.
Leukocytes were isolated from terminal blood samples using centrifugation over a
histopaque gradient (Sigma) in conjunction with erythrolysis using ACK lysing buffer

80
(Life Technologies) according to manufacturer instructions. The resulting leukocyte
pellets were fixed for a minimum of 24 hours in 10% neutral-buffered formalin.
Leukocytes from hamsters inoculated with the same Nipah virus isolate and which were
euthanized at the same time point were pooled, then processed in HistoGel (Thermo
Scientific) according to manufacturer instructions and embedded in paraffin to form a cell
block.
Routine hematoxylin and eosin (H&E) staining, immunohistochemisy (IHC) and
in situ hybridization (ISH) were performed on tissue sections and cell blocks. Nipah virus
antigen was detected by IHC; tissue sections were labeled with a rabbit polyclonal
antiserum against Nipah virus nucleoprotein (1:5000; kindly provided by L. Wang,
CSIRO Livestock Industries, Australian Animal Health Laboratory, Australia).3 Nipah
virus replication was detected in tissue sections by ISH using probes specific for positive
sense Nipah virus nucleoprotein RNA; the method used here has been previously
described.26 All slides were evaluated by a board certified veterinary anatomic
pathologist.

3.3.5

Quantitative Real-Time RT-PCR (qRT-PCR)

Viral RNA was isolated from hamster tissues using the RNeasy Mini kit (Qiagen)
or from hamster blood using the QIAamp Viral RNA Mini kit (Qiagen), according to the
instructions of the manufacturer. 5 µl of RNA was used in a one-step real-time RT-PCR
targeting the Nipah virus nucleoprotein, as described previously,8 using the QuantiFast
kit (Qiagen) according to instructions of the manufacturer. In each run, standard dilutions
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of RNA extracted from a titered virus stock were run in parallel, to calculate TCID50
equivalents in the samples.

3.3.6

Virus Titrations

Virus titrations were performed by end-point titration in Vero C1008 cells. Vero
C1008 cells were inoculated with tenfold serial dilutions of tissue homogenates. One
hour after inoculation of cells with tissue homogenates, the inoculum was removed and
replaced with 200 µl DMEM supplemented with 2% fetal bovine serum, 1 mM Lglutamine, 50 U/ml penicillin and 50 µg/ml streptomycin. Five days after inoculation
with tissue homogenates from NiV-B inoculated hamsters and three days after
inoculation with tissue homogenates from NiV-M inoculated hamsters, cytopathic effect
(CPE) was scored and the TCID50 was calculated from 4 replicates by the SpearmanKarber method.15

3.4

3.4.1

Results

Nipah Virus Replication is Detected at 8 Hours Post Inoculation

In hamsters inoculated intranasally with 5 x 106 TCID50 of NiV-M, viral RNA
was detected by qRT-PCR at 4 hpi in the lung, nasal turbinates, trachea, larynx, cervical
lymph nodes and brain (Figure 3.1). Although viral RNA was found as early as 4 hpi in
several respiratory tract tissues, infectious virus was isolated at 8 hpi in the lung and nasal
turbinates and not until 16 hpi in the trachea and larynx (Figure 3.2). In situ hybridization
(ISH) using probes that targeted the positive sense RNA of the Nipah virus nucleoprotein,
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which is only observed when virus replication occurs, first detected virus replication at 8
hpi in the lung and 16 hpi in the nasal turbinates in 2 out of 4 hamsters at each time point
(Tables 3.1 and 3.2, Figure 3.3). The lack of positive sense viral RNA at 4 hpi in all of
the tissues, in addition to the decrease in detected viral loads in most tissues between 4
hpi and 8 hpi, suggests that the viral RNA detected at 4 hpi by qRT-PCR represented the
administered viral inoculum rather than virus replication. Thus, the first evidence of
Nipah virus replication was detected at 8 hpi.

3.4.2

Nipah Virus Initially Targets the Lung and Nasal Cavity

In hamsters inoculated intranasally with NiV-M, positive sense viral RNA,
indicating virus replication, was detected in type I pneumocytes and bronchiolar
respiratory epithelium at 8 hpi in 2 out of 4 hamsters (Table 3.1). Additionally, positive
sense viral RNA was also detected in alveolar macrophages in 2 out of 4 hamsters at 8
hpi. Starting at 16 hpi, virus replication was observed in respiratory epithelium lining
bronchi in 2 out of 4 hamsters. Immunohistochemistry (IHC) that targeted the Nipah
virus nucleoprotein antigen was used to track virus dissemination throughout the lung
between 4 and 48 hpi; increasing amounts of viral antigen were detected at subsequent
time points (Table 3.3, Figure 3.4). By 16 hpi, viral antigen had spread from alveoli and
bronchioles to the larger airways and was found in the bronchial respiratory epithelium in
2 out of 4 hamsters. In bronchioles, at 16 hpi viral antigen had spread from the
bronchiolar epithelium to the underlying bronchiolar smooth muscle in 1 out of 4
hamsters. Spread of viral antigen to arterial smooth muscle cells in the lung was only
noted at 32 and 48 hpi; viral antigen was not observed in the endothelial cells of these
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vessels. At both time points, vascular involvement was only observed in 1 out of 4
hamsters and affected one to a few small-caliber arteries, but not veins. In the nasal
cavity, infectious virus was detected at 8 hpi. Positive sense viral RNA, indicating virus
replication had occurred, was observed in respiratory and olfactory epithelium at 16 hpi
(Table 3.2). Tracking of viral antigen in the nasal cavity over time showed that
respiratory and olfactory epithelium were infected first, followed by infection of the
submucosal gland epithelium underlying both respiratory and olfactory epithelial cells at
24 hpi (Table 3.4, Figure 3.4). Viral antigen was not observed in the vascular smooth
muscle cells or endothelium in the nasal cavity at any time point.

3.4.3

Nipah Virus Spreads from Nasal Cavity or Lung to Trachea and Larynx

Although infectious virus was detected at 8 hpi in the lung and nasal cavity of
hamsters intranasally inoculated with NiV-M, it was not until later time points that Nipah
virus was detected in the trachea and larynx. At 16 hpi, positive sense viral RNA and
Nipah virus antigen were identified in the trachea in 2 out of 4 hamsters (Figure 3.5).
Additionally, infectious virus was isolated from the trachea and larynx at 16 hpi.
However, IHC first detected viral antigen in the larynx at 32 hpi and positive sense viral
RNA, as analyzed by ISH, was not identified in this tissue at any time point examined
despite detection of infectious virus and viral RNA, by qRT-PCR (Figure 3.5). As ISH
and IHC are evaluated histologically, it is possible that positive sense viral RNA and viral
antigen may have also been present in the larynx at 16 hpi, but were not found in the
exact tissue sections that were labeled. The lack of virus replication, infectious virus and
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viral RNA at 8 hpi in both of these tissues suggests that Nipah virus spreads from one or
both of its initial target organs, the nasal cavity and lung, to the trachea and larynx.

3.4.4

Nipah Virus Disseminates Outside of the Respiratory Tract

Dissemination of Nipah virus through the vascular system was also analyzed. ISH
and IHC were performed on cell blocks made up of peripheral leukocytes collected
during terminal heart bleeds. Positive sense viral RNA and viral antigen were not
observed in peripheral leukocytes at any time point. Additionally, viral RNA was not
detected in the peripheral blood by qRT-PCR (data not shown). These results suggest that
Nipah virus was either not bound to, or replicating in, leukocytes circulating in blood or
levels of virus in the blood were below the limit of detection. Furthermore, even at 48 hpi,
viral antigen and positive sense viral RNA were not detected in the vasculature of any
organ examined, other than the lung. Additionally, lesions associated with Nipah virus
infections of the vascular wall, including vasculitis, fibrinoid change and fibrin thrombi,
were not detected histologically at any time point in any organ, except the lung.
In hamsters intranasally inoculated with NiV-M, lymphoid organs were analyzed
for signs of virus dissemination. Infectious virus was only detected at 48 hpi in the
cervical lymph node in 2 out of 4 hamsters and in the spleen of 1 out of 4 hamsters; viral
titers were low in these animals (Figure 3.2). Positive sense viral RNA and viral antigen
were not detected in the lymphoid organs at any time point.
The central nervous system was also analyzed for evidence of virus dissemination.
Low viral loads were detected by qRT-PCR in a few hamsters in the brain and spinal cord
(Figure 3.1). However, neither infectious virus, viral antigen, nor positive sense viral
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RNA were identified in the central nervous system tissues at any time point (data not
shown). These results suggest that during the first 48 hpi, Nipah virus was not yet
replicating in the brain or spinal cord.

3.4.5

NiV-B Mirrors the Early Target Cells of NIV-M yet Exhibits Slower Virus
Dissemination
Since the human case fatality rates and prevalence of respiratory disease

were different between Nipah virus outbreaks in Malaysia and Bangladesh,4,20,24,28 we
sought to determine whether there were differences in the early pathogenesis of Nipah
virus infections caused by either NiV-M or NiV-B. The same experimental protocols and
analyses were performed on hamsters inoculated with either Nipah virus isolate.
Similar to hamsters inoculated with NiV-M, viral RNA was detected by qRT-PCR
in the respiratory and central nervous systems and cervical lymph nodes at 4 hpi in
hamsters intranasally inoculated with NiV-B (Figure 3.6). Despite the detection of viral
RNA in several tissues at 4 hpi, infectious virus and positive sense viral RNA were first
detected at either 8 or 16 hpi and were only present in respiratory tract tissues (Figure 3.7
and 3.8). Positive sense viral RNA, indicating virus replication, was detected by 8 hpi in
type I pneumocytes and alveolar macrophages in 4 out of 4 hamsters and in bronchiolar
respiratory epithelium in 2 out of 4 hamsters (Table 3.5, Figure 3.8). Similar to NiV-M
inoculated hamsters, the respiratory and olfactory epithelium in the nasal cavity were also
early target cells for virus replication, as observed by ISH (Table 3.6, Figure 3.8). The
presence of Nipah virus antigen in the lung and nasal cavity, as detected by IHC,
mirrored what was detected by ISH (Tables 3.7 and 3.8, Figure 3.9). Unlike NiV-M
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inoculated hamsters, dissemination of viral antigen to pulmonary bronchiolar and arterial
smooth muscle cells was not observed, even at 48 hpi. Spread of viral antigen in the nasal
cavity from the epithelial cells to the underlying submucosal glands took longer in NiV-B
inoculated hamsters and was not detected until 48 hpi; viral antigen was first identified at
24 hpi in NiV-M inoculated hamsters. Similar to NiV-M inoculated hamsters, Nipah
virus appeared to spread from the nasal cavity or lung to the trachea and larynx (Figure
3.10). Widespread vascular dissemination was not detected and infectious virus, viral
antigen and virus replication were not identified in the brain, spinal cord or lymphoid
organs at any time point in NiV-B inoculated hamsters.

3.5

Discussion

In this study, Syrian hamsters were intranasally inoculated with either NiV-M or
NiV-B in order to evaluate the progression of Nipah virus dissemination during the early
stage of infection and to pinpoint early Nipah virus target organs and cells. Identifying
the initial viral target organ and cell types and the route of virus dissemination to
subsequent tissues is vital for determining the most effective route and time frame for
administering antivirals aimed at preventing systemic virus dissemination and severe
disease. In our study, the lung and nasal cavity were identified as early Nipah virus
targets in hamsters inoculated with either Nipah virus isolate. Virus replication was
detected by ISH early in the infection. Positive sense viral RNA, indicating occurrence of
virus replication, was first identified at 8 hpi deep in the lung in type I pneumocytes,
bronchiolar respiratory epithelial cells and alveolar macrophages. The presence of
positive sense viral RNA in alveolar macrophages suggests virus replication occurred
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early in this cell type; however, phagocytosis is a major function of alveolar macrophages
and if virus replication in epithelial cells actually began sometime between our 4 and 8
hpi time points, it cannot be ruled out that the presence of positive sense viral RNA in
macrophages may be due to phagocytosis of virus infected epithelial cells prior to 8 hpi.11
In the lung and nasal cavity, identification of virus infection and replication
occurred first in epithelial cells that lined air spaces, suggesting that these cells were
directly infected after inhalational exposure. At subsequent time points, spread from these
epithelial cell types to adjacent underlying cells, including bronchiolar smooth muscle
cells, arterial smooth muscle cells in the lung and submucosal gland acinar epithelial cells
in the nasal cavity, was identified. Viral infection of the vascular endothelium was not
observed in any tissue at any time point; however, if time points subsequent to 48 hpi
were analyzed it is likely that Nipah virus would have spread from the arterial smooth
muscle cells to the overlying vascular endothelial cells in the lung, potentially followed
by virus dissemination to vessels in other organs and subsequent spread to adjacent
permissive parenchymal cells. After infection of the lung and nasal cavity, epithelial cells
lining the trachea and larynx were targeted by Nipah virus at 16 hpi. Based on the lack of
vascular involvement at this time point, the laryngeal and tracheal epithelial cells were
likely infected by virus particles disseminating through the airways during respiration.
Interestingly, our results showed that in the early phase of infection the spread of
Nipah virus from epithelial cells that lined airways in the lung and nasal cavity to
underlying cells appeared to be faster in hamsters inoculated with NiV-M than with NiVB, suggesting that development of severe disease may occur faster for NiV-M. However,
in studies evaluating late stage Nipah virus disease in Syrian hamsters, results were
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contradictory as to whether disease progression in the respiratory system was faster for
NiV-M or for NiV-B.2,9 Additionally, end-stage lesions in the respiratory tract appeared
to plateau at the same severity level by 4 days post inoculation in Syrian hamsters
inoculated with either Nipah virus isolate,2 indicating that differences noted prior to endstage disease may not in fact significantly impact the overall clinical disease severity or
outcome.
In addition to the respiratory tract, we also analyzed the central nervous system,
lymphoid organs and multisystemic vasculature for evidence of virus dissemination to
non-respiratory tract tissues. Even at 48 hpi, virus infection and replication were not
detected in peripheral leukocytes or vessels outside of the lung. Low viral loads were
observed in the brain and spinal cord in a few NiV-B and NiV-M inoculated hamsters at
24 or 32 hpi, yet infectious virus and virus replication were not noted. Based on our
results, spread of Nipah virus to the brain likely occurred through movement of virus
from the nasal cavity olfactory neurons to the brain by way of the olfactory nerve, rather
than via a hematogenous route. However, since viral loads in the brain were low, we were
unable to detect, or track movement of, viral antigen into the brain by IHC. Spread of
virus from the brain to the thoracolumbar spinal cord may have occurred through the
cerebrospinal fluid; Nipah virus has been detected in the cerebrospinal fluid of infected
humans.6 In the lymphoid organs, infectious virus was detected at 48 hpi in the cervical
lymph nodes of NiV-M inoculated hamsters, but was not present in NiV-B inoculated
hamsters. Lymphatics from the head and neck drain into the cervical lymph nodes, as
such, virus could be transported from the nasal cavity to the cervical lymph nodes
through lymphatic drainage. Infectious virus was only detected at 48 hpi in the spleen of
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a single NiV-M inoculated hamster and was not identified in any NiV-B inoculated
hamsters. Spread of Nipah virus to the spleen may have occurred by a hematogenous
route. Although viremia was not detected at 48 hpi, it is possible that the overall viral
load in the blood was below the level of detection; however, since the spleen functions to
remove pathogens from the blood as blood is filtered through the spleen,1,18,25 Nipah virus
may have accumulated to high enough levels in the spleen that virus could be detected.
Overall, these results suggest that Nipah virus uses airways to initially
disseminate throughout the respiratory tract during the early phase of infection. This may
be followed by dissemination of virus from the nasal cavity to the nervous system by
neural route, potentially as early as 24 hpi, and dissemination of virus to lymph nodes via
lymphatic drainage of the nasal cavity. Dissemination of virus, resulting in virally
infected endothelial cells and smooth muscle cells in blood vessels in multiple organs
does not appear to occur during the first 48 hpi, yet results suggest that this will occur at a
later time point. Since Nipah virus can cause encephalitis that results in severe neurologic
disease in humans and brain stem damage that often causes death, it is important to
prevent virus dissemination to the brain.10,13 Our data suggest that rapid administration of
antivirals into the respiratory tract would be the most effective strategy for preventing
early virus dissemination to the central nervous system, thus potentially lessening disease
severity and the case fatality rate.
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Table 3.1 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in
the Lungs of Syrian Hamsters Inoculated with a Malaysia Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Type I
Pneumocytes
Alveolar
Macrophages
Bronchiolar
Respiratory Epi.
Bronchiolar
Smooth Muscle
Bronchial
Respiratory Epi.
Arterial Smooth
Muscle

8

16

-

-

-

-

++

-

++

-

+++

-

+++

-

-

-

-

-

++

-

++

-

+++

-

+++

-

-

-

-

-

+++

-

+++

-

+++

-

+++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

++

-

+++

-

-

-

-

-

-

-

-

-

-

-

-

-

Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters
in this table correspond to the columns in Tables 3.2, 3.3 and 3.4.
The presence of positive sense Nipah virus RNA was scored in cell types in the lung.
Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ =
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ = multifocal
marked or coalescing to diffuse ISH signal.
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Table 3.2 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in
the Nasal Cavity of Syrian Hamsters Inoculated with a Malaysia Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Respiratory
Epithelium
Olfactory
Epithelium
Submucosal Gland
Epithelium

8

16

NE

-

-

-

-

-

-

-

-

-

-

++

NE

NE

-

-

-

-

-

-

-

-

-

++

NE

NE

-

-

-

-

-

-

-

-

-

-

NE, not examined.
Each column represents a single hamster. The columns representing individual hamsters
in this table correspond to the columns in Tables 3.1, 3.3 and 3.4.
The presence of positive sense Nipah virus RNA was scored in cell types in the nasal
cavity. Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ =
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ = multifocal
marked or coalescing to diffuse ISH signal.
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Table 3.3 Localization of Nipah Virus Antigen by Immunohistochemistry in the Lungs of Syrian Hamsters Inoculated with a
Malaysia Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Type I
Pneumocytes
Alveolar
Macrophages
Bronchiolar
Respiratory Epi.
Bronchiolar
Smooth Muscle
Bronchial
Respiratory Epi.
Arterial Smooth
Muscle

8

16

24

32

48

-

-

-

-

++

-

++

-

++

-

+++

-

-

++

-

-

-

+++

-

+++

++++

-

++

-

-

-

-

-

++

-

++

-

++

-

+++

-

-

++

-

-

+

+++

-

+++

++++

-

++

-

-

-

-

-

+

-

+++

-

++

-

+++

-

-

+++

-

-

++

+++

-

+++

+++

-

++

-

-

-

-

-

-

-

-

-

-

-

+

-

-

-

-

-

-

-

-

-

++

-

-

-

-

-

-

-

-

-

-

-

++

-

++

-

-

+++

-

-

++

++

-

+++

+++

-

+++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

++

+

-

-

-

Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in
Tables 3.1, 3.2 and 3.4.
The presence of Nipah virus antigen was scored in cell types in the lung. Scoring protocol: - = negative; + = focal immunopositivity;
++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ = multifocal marked or coalescing to
diffuse immunopositivity.
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Table 3.4 Localization of Nipah Virus Antigen by Immunohistochemistry in the Nasal Cavity of Syrian Hamsters Inoculated with a
Malaysia Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Respiratory
Epithelium
Olfactory
Epithelium
Submucosal
Gland Epi.

8

16

24

32

48

-

-

-

-

-

-

-

-

+

-

-

+

+

-

NE

++

++

+

+

-

++

++

++

+

-

-

-

-

-

-

-

-

-

-

-

++

+

-

NE

++

++

++

-

-

+++

-

++++

+

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NE

++

++

-

-

-

++

-

+++

-

NE, not examined; Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in
Tables 3.1, 3.2 and 3.3.
The presence of Nipah virus antigen was scored in cell types in the nasal cavity. Scoring protocol: - = negative; + = focal
immunopositivity; ++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ = multifocal marked
or coalescing to diffuse immunopositivity.
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Table 3.5 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in
the Lungs of Syrian Hamsters Inoculated with a Bangladesh Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Type I
Pneumocytes
Alveolar
Macrophages
Bronchiolar
Respiratory Epi.
Bronchiolar
Smooth Muscle
Bronchial
Respiratory Epi.
Arterial Smooth
Muscle

8

16

-

-

-

-

++

++

++

++

+++

+++

++

-

-

-

-

-

++

++

++

++

+++

+++

++

-

-

-

-

-

+

++

-

-

+++

+++

+++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

++

-

-

-

-

++

++

-

-

-

-

-

-

-

-

-

-

-

-

-

Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters
in this table correspond to the columns in Tables 3.6, 3.7 and 3.8.
The presence of positive sense Nipah virus RNA was scored in cell types in the lung.
Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ =
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ = multifocal
marked or coalescing to diffuse ISH signal.
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Table 3.6 Localization of Positive Sense Nipah Virus RNA by In Situ Hybridization in
the Nasal Cavity of Syrian Hamsters Inoculated with a Bangladesh Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Respiratory
Epithelium
Olfactory
Epithelium
Submucosal Gland
Epithelium

8

16

-

-

-

-

-

-

-

-

+

-

+

+

-

-

-

-

-

-

-

-

++

++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Each column represents a single hamster. The columns representing individual hamsters
in this table correspond to the columns in Tables 3.5, 3.7 and 3.8.
The presence of positive sense Nipah virus RNA was scored in cell types in the nasal
cavity. Scoring protocol: - = negative; + = focal in situ hybridization (ISH) signal; ++ =
multifocal mild ISH signal; +++ = multifocal moderate ISH signal; ++++ = multifocal
marked or coalescing to diffuse ISH signal.
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Table 3.7 Localization of Nipah Virus Antigen by Immunohistochemistry in the Lungs of Syrian Hamsters Inoculated with a
Bangladesh Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Type I
Pneumocytes
Alveolar
Macrophages
Bronchiolar
Respiratory Epi.
Bronchiolar
Smooth Muscle
Bronchial
Respiratory Epi.
Arterial Smooth
Muscle

8

16

24

32

48

-

-

-

-

++

-

++

++

+++

+++

++

-

-

-

++

++

++

+++

-

+++

+

-

++

+

-

-

-

-

++

-

++

++

+++

+++

++

-

-

-

++

++

++

+++

-

+++

-

-

+

+

-

-

-

-

+

-

-

+

++

++

+

-

-

-

-

+

+

+++

-

+++

+

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

+

-

-

-

-

-

-

-

-

-

+

-

-

-

-

-

++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in
Tables 3.5, 3.6 and 3.8.
The presence of Nipah virus antigen was scored in cell types in the lung. Scoring protocol: - = negative; + = focal immunopositivity;
++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ = multifocal marked or coalescing to
diffuse immunopositivity.
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Table 3.8 Localization of Nipah Virus Antigen by Immunohistochemistry in the Nasal Cavity of Syrian Hamsters Inoculated with
a Bangladesh Isolate of Nipah Virus
Cell Type

Time Post Inoculation (hours)
4

Respiratory
Epithelium
Olfactory
Epithelium
Submucosal
Gland Epi.

8

16

24

32

48

-

-

-

-

-

-

-

-

++

-

+

-

-

++

+

-

++

NE

+

-

++

-

++

+

-

-

-

-

-

-

-

-

++

+

-

-

-

-

-

-

++

NE

+

-

-

-

+++

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

NE

-

-

-

-

+++

-

NE, not examined; Epi, Epithelium.
Each column represents a single hamster. The columns representing individual hamsters in this table correspond to the columns in
Tables 3.5, 3.6 and 3.7.
The presence of Nipah virus antigen was scored in cell types in the nasal cavity. Scoring protocol: - = negative; + = focal
immunopositivity; ++ = multifocal mild immunopositivity; +++ = multifocal moderate immunopositivity; ++++ = multifocal
marked or coalescing to diffuse immunopositivity.
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Figure 3.1 A-H. qRT-PCR was used to detect viral RNA in the lung (A), nasal turbinates
(B), trachea (C), larynx (D), cervical lymph node (E), spleen (F), brain (G) and spinal
cord (H) at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally inoculated with
NiV-M. Viral loads in the tissues were determined as TCID50 equivalents. In each run,
standard dilutions of RNA extracted from a titered virus stock were run in parallel, to
calculate TCID50 equivalents. Each blue dot indicates a single hamster. Each horizontal
blue line indicates the mean viral load for that time point.
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Figure 3.2 A-F. Virus titration was used to detect infectious virus in the lung (A), nasal
turbinates (B), trachea (C), larynx (D), cervical lymph node (E) and spleen (F) at 8, 16,
24, 32 and 48 hpi in Syrian hamsters intranasally inoculated with NiV-M. Virus titers in
the tissues were determined by titration on Vero C1008 cells. Three days after inoculation
with tissue homogenates from NiV-M inoculated hamsters, cytopathic effect (CPE) was
scored and the TCID50 was calculated from 4 replicates by the Spearman-Karber method.
Each blue dot indicates a single hamster. Each horizontal blue line indicates the mean
virus titer for that time point.
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Figure 3.3 A-F. Positive sense viral RNA, indicating the presence of virus replication,
was detected by ISH in the lung and nasal turbinates at 4, 8 and 16 hpi in Syrian hamsters
intranasally inoculated with NiV-M. Positive sense viral RNA was not identified at 4 hpi
in the lung (A), yet was detected in pneumocytes at 8 and 16 hpi (B, C). Positive sense
viral RNA was not present in the nasal turbinates at 4 or 8 hpi (D, E), but was observed at
16 hpi in the nasal turbinates, as shown here in the respiratory epithelium (F).
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Figure 3.4 A-L. The presence of viral antigen in cells was identified by IHC in the lung
and nasal turbinates at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally
inoculated with NiV-M. Nipah virus antigen was not detected at 4 hpi in the lung (A).
Viral antigen was first detected at 8 hpi in the lung; arrow indicates antigen in
pneumocytes (B). Increasing amounts of viral antigen were detected in pneumocytes at
subsequent time points in the lung (C-F). Viral antigen was also detected in bronchiolar
respiratory epithelium, bronchiolar smooth muscle (black arrow) and arterial smooth
muscle (inset; red arrow) (F). Viral antigen was not detected in the nasal turbinates at 4
or 8 hpi (G, H). Viral antigen was first observed in the nasal turbinates at 16 hpi, as
shown here in the respiratory epithelium (I). Increasing amounts of viral antigen were
detected in olfactory and respiratory epithelium (J-L). The spread of viral antigen to the
submucosal glands was first detected at 24 hpi (J).
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Figure 3.5 A-D. Detection of positive sense viral RNA, by ISH, and viral antigen, by
IHC, in the trachea and larynx of Syrian hamsters intranasally inoculated with NiV-M.
Positive sense viral RNA (A) and viral antigen (B) were identified in respiratory
epithelial cells in the trachea. Positive sense viral RNA was not identified in the larynx in
any hamsters (C); however, viral antigen was detected in the larynx (D).
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Figure 3.6 A-H. qRT-PCR was used to detect viral RNA in the lung (A), nasal
turbinates (B), trachea (C), larynx (D), cervical lymph node (E), spleen (F), brain (G)
and spinal cord (H) at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally
inoculated with NiV-B. Viral loads in the tissues were determined as TCID50 equivalents.
In each run, standard dilutions of RNA extracted from a titered virus stock were run in
parallel, to calculate TCID50 equivalents. Each blue dot indicates a single hamster. Each
horizontal blue line indicates the mean viral load for that time point.
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Figure 3.7 A-D. Virus titration was used to detect infectious virus in the lung (A), nasal
turbinates (B), trachea (C) and larynx (D) at 8, 16, 24, 32 and 48 hpi in Syrian hamsters
intranasally inoculated with NiV-B. Virus titers in the samples were determined by
titration on Vero C1008 cells. Five days after inoculation with tissue homogenates from
NiV-B inoculated hamsters, cytopathic effect (CPE) was scored and the TCID50 was
calculated from 4 replicates by the Spearman-Karber method. Each blue dot indicates a
single hamster. Each horizontal blue line indicates the mean virus titer for that time point.
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Figure 3.8 A-F. Positive sense viral RNA, indicating the presence of virus replication,
was detected by ISH in the lung and nasal turbinates at 4, 8 and 16 hpi in Syrian hamsters
intranasally inoculated with NiV-B. Positive sense viral RNA was not identified at 4 hpi
in the lung (A), yet was detected in pneumocytes at 8 hpi (arrow) and 16 hpi (B, C).
Positive sense viral RNA was not present in the nasal turbinates at 4 or 8 hpi (D, E), yet
was observed at 16 hpi in the nasal turbinates, as shown here in the olfactory epithelium
(F).
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Figure 3.9 A-L. The presence of viral antigen in cells was identified by IHC in the lung
and nasal turbinates at 4, 8, 16, 24, 32 and 48 hpi in Syrian hamsters intranasally
inoculated with NiV-B. Nipah virus antigen was not detected at 4 hpi in the lung (A).
Viral antigen was first detected at 8 hpi in the lung; arrow indicates antigen in
pneumocytes (B). Increasing amounts of viral antigen were detected in pneumocytes at
subsequent time points in the lung (C-F). Viral antigen was also detected in bronchiolar
respiratory epithelium (arrow) (E) and bronchial respiratory epithelium (F). Inset shows
viral antigen in pneumocytes (arrow) (F). Viral antigen was not detected in the nasal
turbinates at 4 or 8 hpi (G, H). Viral antigen was first observed in the nasal turbinates at
16 hpi, as shown here in the olfactory epithelium (I). Increasing amounts of viral antigen
were detected in olfactory and respiratory epithelium (J-L). The spread of viral antigen to
the submucosal glands (arrow) was first detected at 48 hpi (L).

112

Figure 3.10 A-F. Detection of positive sense viral RNA, by ISH, and viral antigen, by
IHC, in the trachea and larynx of Syrian hamsters intranasally inoculated with NiV-B.
Positive sense viral RNA was not detected in the trachea of any hamster (A); however,
viral antigen was observed in epithelial cells lining the trachea (B). Positive sense viral
RNA was identified in epithelial cells lining the larynx (C), although viral antigen was
not detected (D).
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4.1

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) was initially isolated
from a Saudi Arabian man with fatal pneumonia. Since the original case in 2012, MERSCoV infections have been reported in more than 1100 humans and the case fatality rate is
currently 38%. This lineage C Betacoronavirus causes a wide range of disease severity,
ranging from asymptomatic to progressive, fatal pneumonia that may be accompanied by
renal or multiorgan failure. Although the clinical presentation of human MERS-CoV
infection has been documented, there are many facets of this emerging disease that are
still unknown and could be studied using animal models. Several animal models of
MERS-CoV have been developed, including New Zealand white rabbits, transduced or
transgenic mice that express human dipeptidyl peptidase 4, rhesus macaques and
common marmosets. This review provides an overview of the current state of knowledge
on MERS-CoV infection, the probable origin of this virus and the available animal
models. Evaluation of the benefits and limitations of these models will aid in appropriate
model selection for studying viral pathogenesis and transmission as well as for testing
vaccines and antivirals against MERS-CoV.
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4.2

Introduction

Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated
from a man in Saudi Arabia in 2012 and MERS-CoV infections have now been reported
in more than 20 countries.68,72 Originally called human coronavirus-EMC/2012, the virus
was renamed MERS-CoV by the International Committee on Taxonomy of Viruses.19,63
MERS-CoV is an enveloped, non-segmented, single-stranded, positive-sense RNA virus
with a genome of 30,119 nucleotides.63 In humans, MERS-CoV is one of six
coronaviruses that cause respiratory disease; however, it is currently the only known
pathogenic human lineage C Betacoronavirus.30,64 MERS-CoV infections in humans
range from asymptomatic to progressive fatal pneumonia with occasional renal or
multiorgan failure.41,49 To date, published autopsy data from fatal human cases are not
available, the exact route of viral transmission to, and among, humans is unknown and
MERS-CoV-specific countermeasures of disease have yet to be approved. Thus,
development of animal models to study the pathology and pathogenesis of this virus,
routes of viral transmission and the efficacy of treatments and vaccines is critical. Here,
we review the current state of knowledge on MERS-CoV infection in humans and
potential animal reservoirs for the virus and provide an overview and analysis of animal
models of MERS-CoV infection.

4.3

Human MERS-CoV Infections

MERS-CoV was originally reported as a cause of pneumonia in 2012.72 Since the
initial case, a wide spectrum of disease from asymptomatic to severe, fatal pneumonia
has been documented.41,49 More than 1100 human cases of MERS-CoV have been
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identified; with the vast majority occurring in the Arabian Peninsula.67 Initially, MERSCoV predominantly affected middle-aged males; however, as cases continue to be
reported, the gap between males and females has narrowed and all age groups ranging
from children to the elderly have been affected.4,8,9,14,49,52
The median incubation period from infection to development of disease is
approximately 5 days.9 Individuals typically present with respiratory symptoms including
coughing and shortness of breath, often accompanied by nonspecific signs of disease
such as fatigue, myalgia, arthralgia, fever, headaches, vomiting or diarrhea.11,27,41,50,62
Lower respiratory tract disease is most often reported; however, some individuals present
with upper respiratory tract symptoms including a sore throat or rhinorrhea.18,49 In
patients that develop pneumonia, the disease can rapidly progress to acute respiratory
distress syndrome sometimes associated with acute renal failure, multiorgan failure and
death.13,55 The case fatality rate is currently 38%. MERS-CoV infection has also rarely
been associated with secondary complications such as disseminated intravascular
coagulation, hyperkalemia or stillbirth.3,51 Severe disease is most common in individuals
with comorbidities such as hypertension, diabetes mellitus, renal or cardiovascular
disease, obesity, smoking or immunosuppression.9,27,41,49,69 Asymptomatic or mild
MERS-CoV infections mainly occur in previously healthy, immunocompetent
individuals; these cases are being more frequently reported due to increased
surveillance.14,22,61 Ancillary tests have detected multiple abnormalities in complete blood
counts, biochemistry panels and radiographs in MERS-CoV infected patients.
Lymphopenia, neutrophilia, thrombocytopenia and increased levels of c-reactive protein
have all been reported.8,11,50,72 Increases in creatine kinase, alanine aminotransferase,
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lactate dehydrogenase, creatinine and blood urea nitrogen have been identified in some
individuals, suggesting the development of hepatic and renal disease.11,27,50,72 Pulmonary
interstitial infiltrates have been documented in radiographs from individuals with
pneumonia.9,72 MERS-CoV infections are commonly diagnosed by detecting viral RNA
from several specimen types using real-time PCR.54 Samples obtained from the lower
respiratory tract, such as bronchoalveolar lavage samples or sputum, are considered the
most reliable for testing purposes since the highest viral loads have typically been found
in this location.18,27 However, MERS-CoV has also been detected in nasal or
oropharyngeal swabs, urine, feces, serum and blood.23,27,34,44
Humans acquire MERS-CoV through zoonotic transmission and bats and
dromedary camels are thought to serve as a source of infection.28,40,48 Additionally,
reports of nosocomial transmission and limited human-to-human transmission in family
clusters have been documented, with MERS-CoV potentially spreading through
respiratory droplets, direct contact or fomites.9,27,34,38,39,43,44,49,50,57,61

4.4

The Origin of MERS-CoV

Evidence suggests that bats may harbor the ancestor of MERS-CoV, and
potentially, MERS-CoV itself. Several reports have described a genetic link between
MERS-CoV and other coronaviruses detected in bats. The lineage C betacoronaviruses,
Pipistrellus bat coronavirus HKU5 and Tylonycteris bat coronavirus HKU4 are
genetically related to MERS-CoV and likely emerged from a distant common ancestor
centuries ago.36 Lineage C betacoronaviruses identified in European and African
Pipistrellus and Nycteris bats were determined to be genetically similar and
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phylogenetically related to MERS-CoV.7 Additionally, in Bisha, Saudi Arabia a few
months after the first human case of MERS-CoV infection was documented, a short
coronavirus sequence fragment consisting of 190 nucleotides, which represented the viral
RNA-dependent RNA polymerase, was isolated from bat feces and shown to share 100%
sequence identity with the original MERS-CoV isolate from the same geographic
region.42
Although MERS-CoV may have originated in insectivorous bats, humans do not
commonly interact with these species, thus limiting the opportunities for viral
transmission. Conversely, direct contact between humans and dromedary camels occurs
on a regular basis in regions with high numbers of reported human MERS-CoV cases and
dromedary camels have been implicated as a source for human MERS-CoV infections.
Neutralizing antibodies against MERS-CoV, or a closely related virus, have been
detected in dromedary camel serum samples collected from several Middle Eastern and
African countries; seropositivity dated back to 1983.6,15,32,33,40,45,46,53,60 Moreover, MERSCoV RNA has been identified in nasal and conjunctival swabs, milk, and rarely rectal
swabs from dromedary camels.5,12,15,28,40,48,59,71 Although MERS-CoV seropositivity is
more common in adult camels; MERS-CoV RNA is most often detected in nasal swabs
from juvenile camels suggesting that active infections typically occur in younger
camels.5,45 MERS-CoV infections in camels appear to be acute and transient; most
infected camels are asymptomatic, however, some camels develop rhinorrhea and an
increase in body temperature.1,10,15,40 Experimental inoculation of young adult dromedary
camels with MERS-CoV has been shown to cause mild disease consisting of
degeneration and necrosis of the respiratory epithelium in the upper and lower respiratory
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tract in the absence of pneumonia.1 Viral antigen and high levels of infectious virus were
detected in affected tissues while the nasal turbinate respiratory epithelium was identified
as the main site of virus replication.1 High amounts of infectious virus were isolated from
nasal discharge despite development of only mild clinical disease,1 which may result in
MERS-CoV infections being overlooked, leading to undetected viral transmission among
camels and between camels and humans.
Epidemiologic data have suggested a link between MERS-CoV infections in
camels and humans. Direct contact with camels or drinking of unpasteurized camel milk
has been reported prior to MERS-CoV infection in some humans.41,55 Genetically similar,
or identical, viral sequences have been isolated from camels and individuals caring for
these animals, with serologic data in one case providing evidence for camel-to-human
transmission.10,28,40 Although the exact mode of transmission between camels and
humans is unknown, it is speculated that transmission may occur through direct contact,
ingestion of unpasteurized camel milk, or contact with respiratory droplets or nasal
secretions, which have been shown to carry high viral loads.1,9,26,41 Despite the high
prevalence of MERS-CoV in camels, viral transmission from camels to humans appears
to be limited and multiple countries with seropositive camels have yet to detect MERSCoV infections in humans.17,31,46

4.5

MERS-CoV Species Tropism

Dipeptidyl peptidase 4 (DPP4, also known as CD26) has been identified as the
receptor for the MERS-CoV spike protein (S) and is required for viral binding and entry
into host cells.56 DPP4 is a type II transmembrane glycoprotein that is expressed on
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epithelial and endothelial cells throughout the body.35 Although DPP4 is evolutionarily
conserved, differences in the amino acids present in its extracellular domain, which binds
MERS-CoV S, have been noted among various animal species and humans. Specifically,
14 amino acids in DPP4 appear to be critical in determining whether the MERS-CoV S
can bind to DPP4.66 MERS-CoV S cannot bind to DPP4 in species that have significant
differences in these 14 amino acids, such as ferrets, hamsters and mice, thus these species
are resistant to infection.37,65 Species with few or no differences in the 14 amino acids can
be infected by MERS-CoV, including rhesus macaques, common marmosets and
camels.24,47,65 In addition to analyzing the DPP4 amino acid sequence, evaluation of the
binding energies between MERS-CoV and DPP4 has proven useful in assessing whether
MERS-CoV S can bind to DPP4 from different species. A low binding energy between
DPP4 and MERS-CoV S has been associated with susceptibility to MERS-CoV infection;
whereas high binding energies are reported between MERS-CoV S and DPP4 from
nonpermissive species.24,65 Determination of binding energies can guide the selection of
animal species when developing animal models of MERS-CoV infection.

4.6

Animal Models of MERS-CoV Infection

As indicated above, several laboratory animal species that are often used to model
viral diseases are not susceptible to MERS-CoV infection due to differences in critical
amino acids in the S-binding domain of DPP4. Multiple strains of wildtype and knockout
mice, Syrian hamsters and ferrets have all been shown to be resistant to MERS-CoV
infection.16,20,58 Despite a lack of conventional small animal models, researchers have
identified several other species that are susceptible to MERS-CoV infection, including
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rabbits, human DPP4 transduced or transgenic mice, rhesus macaques and common
marmosets (summarized in Tables 4.1 and 4.2). Below, each of these animal models of
MERS-CoV are discussed in detail.

4.6.1

Rabbits

New Zealand white rabbits have been described as an animal model of
asymptomatic MERS-CoV infection (Table 4.1).29 Rabbits were inoculated with a total
dose of 5 x 106 TCID50 of MERS-CoV through intratracheal and intranasal routes and
then euthanized 3, 4 or 21 days post inoculation (dpi). Clinical signs, including weight
loss, were not observed in infected rabbits. Gross lesions were not reported in any organ
examined. Microscopically, lesions were detected in the upper and lower respiratory tract
at 3 and 4 dpi. In the nasal cavity, there was a mild to moderate infiltration of heterophils
that in some cases was accompanied by epithelial necrosis and regeneration (Figure 4.1
A). The lungs exhibited mild heterophilic infiltration in alveolar septa and lumina,
predominantly around terminal bronchioles (Figure 4.1 B). Type II pneumocyte
hypertrophy and hyperplasia of bronchus-associated lymphoid tissue were also observed.
Virus was detected in tissues in the upper and lower respiratory tract by
quantitative real-time PCR (qRT-PCR), in situ hybridization (ISH) and
immunohistochemistry (IHC) (Table 4.2). Microscopically, viral antigen was observed in
respiratory and olfactory epithelium in the nasal cavity, where it colocalized with lesions,
and was present in the lungs in type I and type II pneumocytes and epithelium lining
bronchi and bronchioles. Additionally, virus titration revealed the presence of infectious
virus in nasal swabs up to 7 dpi.
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4.6.2

Mice

Although wildtype mice are not susceptible to MERS-CoV infection,16 two mouse
models of MERS-CoV infection have been developed by expressing human DPP4 in
these animals (summarized in Tables 4.1 and 4.2). In the first model, an adenoviral vector
was used to induce transient expression of human DPP4 in the lungs of BALB/c mice,
C57BL/6 mice and multiple knockout mouse strains.73 Human DPP4 was only expressed
by epithelial cells lining the airways and alveoli. After human DPP4 transduction, the
mice were inoculated intranasally with 1 x 105 plaque forming units of MERS-CoV.
Clinical signs in the human DPP4 transduced wildtype mice were minimal and
characterized by lack of weight gain in young mice and mild weight loss in older mice.
Mice exhibited mild pulmonary gross lesions which corresponded to peribronchial and
perivascular inflammation that developed into interstitial pneumonia (Figure 4.1 C, D).
IHC showed MERS-CoV antigen was colocalized with human DPP4 expression in the
lungs. Virus replication was detected in the lungs by 2 dpi; however, viral infection was
transient. Clearance of MERS-CoV from the lungs was faster in younger mice.
Transduced knockout mice, which had impaired immune systems such as a lack of type-I
IFN signaling (IFNAR-/-), typically exhibited earlier, more severe clinical signs and
gross and microscopic lesions than infected transduced wildtype mice (Figure 4.1 E, F).
In all mouse strains, gross and microscopic lesions and virus replication were not present
in organs outside of the respiratory tract, which fits with the lack of detectable human
DPP4 in these tissues.
For the second mouse model, transgenic mice were developed that globally
expressed human DPP4, including on their pulmonary pneumocytes, renal epithelium,
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neurons in the brain and endothelial cells in multiple tissues.2 Five to seven week old
transgenic mice expressing human DPP4 were intranasally inoculated with 106 TCID50 of
MERS-CoV. The transgenic mice exhibited severe, progressive respiratory disease.
Infected mice lost weight, were lethargic and exhibited rapid, shallow breathing. By 6 dpi,
the infection was fatal in 100% of the mice. Gross lesions were only noted in the lungs;
microscopic lesions were observed in the lungs and brain (Figure 4.2 A-D). Pulmonary
gross lesions were characterized as red areas of consolidation that were more extensive at
4 dpi than 2 dpi. Histologically, mice had bronchointerstitial pneumonia with
perivasculitis that was more severe at 4 dpi than 2 dpi. A single mouse exhibited
perivascular cuffing in the brain.
In the transgenic mice, high levels of infectious virus (approximately 107
TCID50/g) were detected in the lung at 2 dpi, while lower levels (approximately 104
TCID50/g) were detected at 4 dpi. Infectious virus was only detected at 4 dpi in the brain;
the mean viral titer in the brain was 7 x 104 TCID50/g. Viral RNA was detected not only
in the lung and brain, but also in visceral organs such as the heart and spleen, suggesting
widespread viral dissemination had occurred. Infectious virus and viral RNA were not
present in the kidneys. Through IHC, viral antigen was detected in type I and type II
pneumocytes in the lungs and microglia, astrocytes and neurons in the brain. Based on
the results, it appeared that the respiratory system was the earliest target for MERS-CoV.

4.6.3

Rhesus Macaques

Koch’s postulates for MERS-CoV were fulfilled in rhesus macaques, which were
the first animal model developed for MERS-CoV infection. Rhesus macaques exhibited
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acute, transient, mild to moderate respiratory disease after either intratracheal inoculation
with 6.5 x 107 TCID50 of MERS-CoV70 or inoculation with a total dose of 7 x 106 TCID50
of MERS-CoV via the ocular, oral, intratracheal and intranasal routes (Table 4.1).21,25,47
Infected macaques exhibited respiratory clinical signs such as tachypnea, deep abdominal
breathing and coughing.21,47 Nonspecific signs of illness such as anorexia, hunched
posture and fever were also reported.21,47,70 Clinical signs were observed by 1 dpi and
resolved as early as 4 dpi.21 Correspondingly, serial complete blood counts showed
development of a lymphopenia and leukocytosis accompanied by neutrophilia 1 dpi,
which resolved by 3 dpi.21
Rhesus macaques that were euthanized at either 3 or 6 dpi developed gross lesions
only in the lungs; lesions consisted of firm, edematous, bright to dark red discolored foci
(Figure 4.2 E).47,70 Histologic pulmonary lesions were described as either an interstitial
pneumonia70 or a bronchointerstitial pneumonia which centered on terminal bronchioles,
with development of hyaline membranes and type II pneumocyte hyperplasia (Figure 4.2
F).21,25 In pulmonary lesions and serum, transient upregulation of proinflammatory
mediators, including interleukin-6 and chemokine (C-X-C motif) ligand 1, were
identified.21 Additionally, MERS-CoV specific neutralizing antibodies were detected in
serum samples as early as 7 dpi.70
Infectious virus was isolated from the lungs47,70 (peak titer was approximately 105
TCID50/gram) and MERS-CoV RNA was detected in several upper and lower respiratory
tract tissues, including the lungs, nasal mucosa, trachea and bronchi (Table 4.2).21
MERS-CoV RNA was also identified in nasal swabs, bronchoalveolar lavage samples
and a few oropharyngeal swabs.21 Despite the presence of viral RNA and evidence for
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viral shedding from the upper respiratory tract, lesions and virus replication were only
observed in lower respiratory tract tissues with virus replication occurring in type I and
type II pneumocytes.21 Sites of virus replication and the location of viral antigen, as
determined by IHC, correlated with the reported sites of cellular expression of DPP4 in
the lungs of rhesus macaques.21,65 Viral antigen in the lung was exclusively present in
areas of pneumonia.21,70 Viral RNA was not present in blood or any visceral organs,
including the kidney.21,70

4.6.4

Common Marmosets

MERS-CoV caused severe, potentially lethal respiratory disease in common
marmosets inoculated with a total dose of 5.2 x 106 TCID50 of MERS-CoV administered
through a combination of ocular, oral, intratracheal and intranasal routes (Table 4.1).24
Infected marmosets developed moderate to severe clinical signs which necessitated early
euthanasia of two out of nine marmosets. Clinical signs included tachypnea, labored or
shallow breathing, cyanosis, hemorrhagic oral discharge, anorexia and hunched posture.
Clinical signs were first noted 1 dpi, peaked at 4-6 dpi and resolved by 13 dpi.
Correspondingly, radiographs showed pulmonary interstitial infiltration as early as 1 dpi;
infiltrates were no longer evident by 13 dpi.
Gross lesions were present only in the lungs of marmosets necropsied 3, 4 or 6 dpi.
Affected lung lobes were dark red, edematous and failed to collapse (Figure 4.2 G).
Microscopically, the pulmonary gross lesions corresponded to foci of bronchointerstitial
pneumonia that centered on terminal bronchioles and extended into adjacent parenchyma
(Figure 4.2 H). The pneumonia was widespread, moderate to severe and in some cases
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the lesions diffusely affected the examined tissue. The pneumonia was characterized by
hyaline membranes, alveolar edema, hemorrhage, fibrin and type II pneumocyte
hyperplasia often with severe airway lesions affecting bronchi and bronchioles. In foci of
pneumonia, there was upregulation of RNA for molecules involved in proinflammatory
and antiviral pathways and fibrogenesis.
IHC detected abundant MERS-CoV antigen in type I and type II pneumocytes and
macrophages within foci of pneumonia (Table 4.2). ISH indicated that type I
pneumocytes and alveolar macrophages were the main sites of virus replication and IHC
showed that these cell types expressed DPP4. High levels of viral RNA were detected in
the lung while lower levels were present in upper respiratory tract tissues and nasal and
oropharyngeal swabs. Infectious virus was isolated from both upper and lower respiratory
tract tissues; the peak pulmonary titer was approximately 107 TCID50/g. MERS-CoV
RNA was also detected in several visceral organs, including the kidney, and in blood
from marmosets necropsied 6 dpi or prior. Identification of viremia and viral RNA in
multiple organ systems suggested that MERS-CoV widely disseminated throughout the
body of marmosets; however, lesions were only present in the respiratory tract.

4.7

Advantages and Limitations of Animal Models of MERS-CoV Infection

Several animal models of MERS-CoV infection have been developed, each of
which has its own set of benefits and limitations (summarized in Table 4.3). Rabbits,
human DPP4 transduced and transgenic mice, rhesus macaques and common marmosets
were all susceptible to MERS-CoV infection, although disease severity was markedly
different among these animal models. New Zealand white rabbits shed MERS-CoV from
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their upper respiratory tract and could potentially be used to study MERS-CoV
transmission; however, they are not suitable for studying clinical disease progression as
they remained asymptomatic after MERS-CoV inoculation. Overall, this model seems to
be of limited value. Human DPP4 transduced mice could be used to model mild MERSCoV disease, as they exhibited mild, transient clinical disease and pulmonary lesions,
although respiratory clinical signs were not noted. An increase in clinical disease severity
with earlier onset of gross and microscopic lesions was achieved by transducing
immunodeficient knockout mice. These mice could be used to study the impact of
different aspects of the immune system on MERS-CoV disease. However, the human
DPP4 transduced mouse model is of limited value for screening antivirals and vaccines
since disease and human DPP4 expression are transient. Currently, the human DPP4
transgenic mouse is the only available small animal model of severe, lethal MERS-CoV
respiratory disease. However, these mice globally express human DPP4 which resulted in
development of both respiratory and nervous system lesions, which may not be
representative of human MERS-CoV infection. Nevertheless, this model is ideal for
screening the efficacy of antivirals and vaccines.
Two nonhuman primate models of MERS-CoV infection develop both clinical
respiratory disease and pneumonia. The disease in rhesus macaques was transient and
similar to mild human cases of MERS-CoV, while common marmosets modeled severe,
potentially lethal respiratory disease. In comparison to the small animal models, the
nonhuman primates have respiratory and immune systems that are more similar to
humans. Additionally, the larger size of the macaques allowed repeated blood sampling,
which showed macaques developed complete blood count abnormalities comparable to
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humans. Both nonhuman primate models, however, have disadvantages in regards to
difficulties in handling in biocontainment, costs and animal ethics. Nevertheless, both
models can satisfy confirmatory efficacy testing requirements for vaccines and antivirals
under the Food and Drug Administration Animal Efficacy Rule; however, the lower body
weight and development of more severe disease makes common marmosets better suited
for antiviral testing.
Acute renal failure has been reported in some humans with MERS-CoV infections,
although this has not been observed in any of the available animal models. However,
when present in humans, acute renal failure appears to develop late in the disease course
and is thought to occur secondary to shock, or in association with previous renal disease,
rather than as a result of viral-induced injury. In support of this, common marmosets
exhibited viremia and viral RNA was detected in their kidneys despite a lack of renal
disease, suggesting that renal failure is not a direct consequence of MERS-CoV infection.

4.8

Conclusions

Taken together, the animal models reviewed here replicated the wide range of
disease severity observed in MERS-CoV infected humans, which spans from
asymptomatic to severe, fatal pneumonia. Although each model had important limitations,
the available animal models can be used to address current gaps in our knowledge of
MERS-CoV disease. Appropriate selection of the most suitable animal model will allow
researchers to study the pathogenesis and transmission of MERS-CoV and development
and testing of antivirals and vaccines.
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Table 4.1 Summary of the inoculation route and dose, clinical disease and gross and microscopic lesions that develop in animal
models of Middle East respiratory syndrome coronavirus infection.
Animal Species

Clinical Disease

Gross Lesions

Microscopic Lesions

Reference Number

New Zealand
White Rabbits

Inoculation Route
and Dose
IT, IN
5 x 106 TCID50

Asymptomatic

Absent

Heterophilic rhinitis, pulmonary
interstitial heterophilic infiltration

29

hDPP4 Transduced
Mice

IN
105 PFU

Lack of weight gain or
mild weight loss

Mild pulmonary
congestion and
inflammation

Pulmonary perivascular and
peribronchial inflammation;
interstitial pneumonia

73

hDPP4 Transgenic
Mice

IN
106 TCID50

Pulmonary
consolidation

Bronchointerstitial pneumonia;
perivascular cuffing in the brain

2

Rhesus Macaques

OC, oral, IT, IN
7 x 106 TCID50

Severe respiratory
disease, weight loss,
100% fatal
Mild to moderate
respiratory disease

Interstitial pneumonia

Bronchointerstitial pneumonia

21, 25, 47

IT
6.5 x 107 TCID50

Fever

Pulmonary
congestion

Interstitial pneumonia

70

OC, oral, IT, IN
5.2 x 106 TCID50

Severe respiratory
disease, potentially fatal

Interstitial pneumonia

Widespread bronchointerstitial
pneumonia

24

Common
Marmosets

IT, intratracheal; IN, intranasal; OC, ocular; TCID50, 50% tissue culture infectious dose; hDPP4, human dipeptidyl peptidase 4;
PFU, plaque forming units.
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Table 4.2 Summary of the tissues and cell types containing viral RNA, viral antigen or
infectious virus in animal models of Middle East respiratory syndrome coronavirus
infection.
MERS-CoV
RNAa
URT
Lung
Tracheobronchial LN

MERS-CoV Antigenb

hDPP4
Transduced Mice

N/D

hDPP4
Transgenic Mice

Animal Species

Infectious
Virus
Lung

Reference
Number
29

Lung

Lung

73

Lung
Brain
Visceral organs

Type I and type II pneumocytes
Microglia, astrocytes, neurons

Lung
Brain

2

Rhesus
Macaques

URT
Lung
Mediastinal LN

Type I and type II pneumocytes
Alveolar macrophages

Lung

21, 25, 47,
70

Common
Marmosets

URT
Lung
Mediastinal LN
Blood
Visceral organs

Type I pneumocytes
Alveolar macrophages

Lung
Nasal mucosa
Trachea

24

New Zealand
White Rabbits

Nasal olfactory and respiratory
epithelium
Bronchial and bronchiolar
epithelium
Type I and type II pneumocytes

MERS-CoV, Middle East respiratory syndrome coronavirus; LN, lymph nodes; N/D, not
determined; TCID50, 50% tissue culture infectious dose; URT, upper respiratory tract
tissues. aMERS-CoV RNA was detected by quantitative real-time PCR. bMERS-CoV
antigen was detected by immunohistochemistry.
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Table 4.3 Summary of the advantages and limitations of animal models of Middle East
respiratory syndrome coronavirus infection.
Animal Species
New Zealand White
Rabbits

Advantages
Inexpensive and easy to obtain

Limitations
No clinical disease
Develop mild pulmonary lesions

hDPP4 Transduced
Mice

Mice can be generated rapidly
Mice of various genetic backgrounds can be
transduced
Easy to handle and house
Reagents and assays are widely available

Clinical disease is transient
Disease is reliant on transduction
efficacy
hDPP4 is expressed transiently and
only in the lungs

hDPP4 Transgenic
Mice

Model severe, fatal MERS-CoV infection
Easy to handle and house
Reagents and assays are widely available
Useful for screening antivirals and vaccines

Exhibit global overexpression of
hDPP4

Rhesus Macaques

Model mild MERS-CoV infection
Repeated blood sampling is possible
Reagents available for immunological analysis
Respiratory and immune systems similar to
humans
Useful for confirming vaccine efficacy testing

Disease is transient
Expert husbandry required
Expensive to obtain
Ethical concerns

Common Marmosets

Model severe, potentially fatal MERS-CoV
infection
Respiratory and immune systems similar to
humans
Useful for confirming antiviral and vaccine
efficacy testing

Expert husbandry required
Expensive to obtain and of limited
availability
Ethical concerns
Few species-specific reagents
available

hDPP4, human dipeptidyl peptidase 4; MERS-CoV, Middle East respiratory syndrome
coronavirus.
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Figure 4.1 A. Middle East respiratory syndrome coronavirus (MERS-CoV) infection,
nasal cavity, New Zealand white rabbit. Mild heterophilic infiltration of the nasal cavity
respiratory epithelium (arrow). Hematoxylin and eosin (HE). B. MERS-CoV infection,
lung, New Zealand white rabbit. Rare heterophilic infiltration in the alveolar septa
(arrow). HE. C-F. MERS-CoV infection, mouse, lung. Images for C-F were taken 7 days
post inoculation (dpi). C. Pulmonary congestion and inflammation in a C57BL/6 human
DPP4 (hDPP4) transduced mouse. D. Mild peribronchiolar and perivascular
inflammation in a C57BL/6 hDPP4 transduced mouse. HE. E. Pulmonary congestion and
inflammation in an hDPP4 transduced mouse that lacked type-I IFN signaling
(IFNAR-/-). The pulmonary lesions were more severe than in the C57BL/6 hDPP4
transduced mice. F. Moderate peribronchiolar and perivascular inflammation in an
IFNAR-/- hDPP4 transduced mouse. HE.
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Figure 4.2 A-D. Middle East respiratory syndrome coronavirus (MERS-CoV) infection,
mouse, lung. Images for A and B were taken 2 days post inoculation (dpi) and C and D
were taken 4 dpi. A. Pulmonary consolidation in an hDPP4 transgenic mouse. B.
Bronchointerstitial pneumonia in an hDPP4 transgenic mouse. Hematoxylin and eosin
(HE). C. Pulmonary consolidation in an hDPP4 transgenic mouse. D. Bronchointerstitial
pneumonia in an hDPP4 transgenic mouse. HE. E-H. MERS-CoV infection at 3 dpi,
nonhuman primate, lung. E. Interstitial pneumonia, seen as dark red foci, in a rhesus
macaque. F. Bronchointerstitial pneumonia with infiltration of neutrophils and
macrophages in a rhesus macaque. HE. G. Interstitial pneumonia, seen as dark red foci,
in a common marmoset. H. Bronchointerstitial pneumonia with bronchiolar erosions
(arrow) and infiltration of neutrophils and macrophages in a common marmoset. HE.
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5.1

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified
in a human with severe pneumonia in 2012. Since then, infections have been detected in
more than 1000 individuals with disease severity ranging from asymptomatic to severe,
fatal pneumonia. To elucidate the pathogenesis of this virus and investigate mechanisms
underlying disease severity variation in the absence of autopsy data, a rhesus macaque
and common marmoset model of MERS-CoV disease were analyzed. Rhesus macaques
developed mild disease and common marmosets exhibited moderate to severe, potentially
lethal, disease. Both nonhuman primate species exhibited respiratory clinical signs post
inoculation, which were more severe and of longer duration in the marmosets, and
developed bronchointerstitial pneumonia. In marmosets, the pneumonia was more
extensive with development of severe airway lesions. Quantitative analysis showed
significantly higher levels of pulmonary neutrophil infiltration and higher amounts of
pulmonary viral antigen in marmosets. Pulmonary expression of the MERS-CoV receptor,
dipeptidyl peptidase 4, was similar in marmosets and macaques. These results suggest
that increased virus replication and the immune response to MERS-CoV infection likely
play a role in pulmonary pathology severity. Together, the rhesus macaque and common
marmoset models of MERS-CoV span the wide range of disease severity reported in
MERS-CoV-infected humans, which will aid in investigating MERS-CoV disease
pathogenesis.
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5.2

Introduction

Middle East respiratory syndrome coronavirus (MERS-CoV) was first isolated in
2012 from a person with fatal acute pneumonia in Saudi Arabia.29 Since the initial case,
more than 1000 human cases of MERS-CoV infection have been detected, mainly in or
near the Arabian Peninsula.6,27 Dromedary camels, common in the Arabian Peninsula, are
thought to serve as a reservoir for MERS-CoV,2 which may in part explain the clustering
of human MERS-CoV infections in this geographic location. The exact route of
transmission of MERS-CoV from camels to humans has not been identified, although
dromedary camels infected with MERS-CoV have been shown to secrete high amounts of
infectious virus in their nasal discharge1 and viral RNA has been detected in their milk.21
MERS-CoV disease ranges from asymptomatic to severe, fatal pneumonia with
acute respiratory distress syndrome occasionally accompanied by renal failure or
gastrointestinal disease.28 Most patients present with a fever and respiratory symptoms,
which rapidly progress to pneumonia. The most common respiratory symptoms are
attributed to lower respiratory tract disease and include dyspnea and coughing.22 Few
individuals solely develop mild upper respiratory tract symptoms, such as a sore
throat.5,22 Severe disease, and death, due to MERS-CoV infection is most common in
individuals affected by comorbidities, including diabetes, renal or cardiac disease and
hypertension.4 The current case fatality rate is approximately 38%; however, no autopsy
reports detailing the lesions in fatal infections have been published to date.27 In order to
elucidate the pathogenesis MERS-CoV infection and investigate mechanisms underlying
the variation in disease severity, two nonhuman primate models were developed. These
models simulated the wide range of disease severity seen in infected humans. Post-
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MERS-CoV inoculation, rhesus macaques developed mild to moderate disease while
common marmosets exhibited moderate to severe, potentially lethal, disease.7,8
Clinical description and virology of MERS-CoV infection in the rhesus macaque
and common marmoset models have been reported.7,8 Here we focus on detailed and
specific histopathology aspects of the respiratory tract of infected animals to establish the
mechanism of pathogenicity. To this end, we scored and quantitatively analyzed the
bronchointerstitial pneumonia in both nonhuman primate species post-MERS-CoV
inoculation and quantified MERS-CoV antigen in the lungs. Increased numbers of
neutrophils in the lung and higher amounts of MERS-CoV antigen were observed in
marmosets. However, marmosets and macaques had similar pulmonary expression of the
MERS-CoV receptor, dipeptidyl peptidase 4. These results suggest that increased
pulmonary virus replication and a robust immune response to MERS-CoV infection may
play a role in pulmonary lesion severity, with higher viral loads and a more pronounced
acute inflammatory response observed in marmosets.

5.3

5.3.1

Materials and Methods

Ethics and Biosafety Statements

All animal experiments were approved by the Rocky Mountain Laboratories
(RML) Institutional Animal Care and Use Committee and were performed following the
guidelines of the Association for Assessment and Accreditation of Laboratory Animal
Care, International (AALAC) by certified staff in an AALAC-approved facility. All
infectious work with MERS-CoV was approved by the Institutional Biosafety Committee
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(IBC) and performed in a high containment facility at RML. Sample inactivation was
performed according to standard operating procedures (SOP) approved by the IBC for
removal of specimens from high containment.

5.3.2

Nonhuman Primates

Archived tissue blocks from nine rhesus macaques (five males, four females; aged
4-10 years) inoculated with a total dose of 7 x 106 50% tissue culture infectious dose
(TCID50) of MERS-CoV and seven common marmosets (seven males; aged 2-6 years)
inoculated with a total dose of 5.2 x 106 TCID50 of MERS-CoV, as described previously,
7-9,16

were analyzed histologically. The rhesus macaques (RM1-9) and common

marmosets (CM1-7) were randomly assigned a number. Necropsies of the animals were
scheduled for 3 days post inoculation (dpi) (CM1-3, RM1-6) and 6 dpi (CM4-6 and RM
7-9). The remaining common marmoset (CM7) was not originally scheduled for
euthanasia, instead it was to be used to study long-term survival; however, due to
development of severe clinical signs this animal was euthanized 4 dpi. A complete set of
tissues from each animal was collected at necropsy.

5.3.3

Histopathology and Immunohistochemistry

Histopathology and immunohistochemistry (IHC) were performed on rhesus
macaque and common marmoset tissues. Tissues were fixed according to SOP for a
minimum of 7 days in 10% neutral-buffered formalin, embedded in paraffin and stained
with hematoxylin and eosin (H&E). The severity of the bronchointerstitial pneumonia
was scored in a non-masked manner by a board certified veterinary pathologist on a scale
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of 0 to 4. 0 = no lesions present. 1 = few inflammatory foci present; alveolar septa
minimally thickened by congestion, neutrophils and macrophages; few neutrophils and
macrophages infiltrate alveoli. 2 = multiple inflammatory foci present in one or more
lobes; alveolar septa mildly thickened by congestion, neutrophils and macrophages;
neutrophils and macrophages mildly infiltrate alveoli. 3 = multiple inflammatory foci
present within a single lung lobe; alveolar septa moderately thickened by congestion,
neutrophils and macrophages; neutrophils and macrophages moderately infiltrate alveoli;
small amounts of fibrin and edema in alveoli. 4 = multifocal to coalescing inflammatory
foci present within a single lung lobe; alveolar septa markedly thickened by congestion,
neutrophils and macrophages; large numbers of neutrophils and macrophages, fibrin and
edema in alveoli.
IHC with a rabbit polyclonal antiserum against HCoV-EMC/2012 (1:1000, RML,
Hamilton, MT)12 as a primary antibody was used to detect MERS-CoV antigen. IHC was
further used to detect neutrophils (polyclonal goat anti-myeloperoxidase, 1:450, R&D
Systems, Minneapolis, MN), T cells (monoclonal rabbit anti-CD3, pre-diluted, Ventana,
Tucson, AZ), B cells (polyclonal rabbit anti-CD20, 1:100, Thermo Scientific, Waltham,
MA), macrophages (polyclonal rabbit anti-Iba1, 1:1000, RML, Hamilton, MT), epithelial
cells (polyclonal rabbit anti-pan cytokeratin, 1:50, Novus Biologicals, Littleton, CO) and
dipeptidyl peptidase 4 (polyclonal rabbit anti-CD26, 1:400, Abcam, Cambridge, MA).
Sections of lung from animals necropsied 3 dpi that were labeled for MERS-CoV antigen
or inflammatory cell markers were digitized using an Aperio Digital Slide Scanner (Leica,
Wetzler, Germany) and analyzed using the positive pixel count algorithm in ImageScope
version 12.1.0.5029 (Leica). The ImageScope positive pixel count algorithm quantified
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the percentage of the pulmonary tissue that was positively labeled for MERS-CoV
antigen or a specific type of inflammatory cell and the percentage of pulmonary tissue
that did not express the IHC marker of interest, but which was labeled by a background
stain. Positive pixel count algorithm calculations are based on the amount of a specific
stain present in a digitized slide and do not include non-stained areas such as spaces filled
with air. The lung lobe section that was most severely affected by bronchointerstitial
pneumonia was analyzed in each animal.

5.3.4

Statistical Analysis

Statistical analyses were performed using the unpaired student’s t-test. P < 0.05
was considered statistically significant. All statistics were performed using GraphPad
Prism version 6.02 (GraphPad Software, Inc., La Jolla, CA).

5.4

5.4.1

Results

Widespread Bronchointerstitial Pneumonia Develops in Common Marmosets

Macaques and marmosets developed bronchointerstitial pneumonia
predominantly centered on terminal bronchioles.7-9,16 In rhesus macaques, the pulmonary
lesions ranged from mild to severe; however, even in lung lobes with severe lesions, the
lesions were multifocal and often surrounded by large areas of normal lung tissue (Figure
5.1 A, C). The bronchointerstitial pneumonia in common marmosets was of moderate to
marked severity and was multifocal to coalescing, with some lobes diffusely affected
(Figure 5.1 B, D). At 3 and 6 dpi, the severity of the bronchointerstitial pneumonia in

152
each lung lobe was scored on a scale of 0-4. The average histologic score for the
pneumonia was significantly higher (P < 0.05) in the marmosets than the macaques at 3
dpi, 3.2 versus 1.3 respectively, and at 6 dpi, 3.3 versus 1.1 respectively (Figure 5.1 E, F).
The more severe bronchointerstitial pneumonia that developed in common marmosets fit
with the more severe respiratory clinical signs and more extensive pulmonary gross
pathology that has previously been reported in common marmosets as compared to rhesus
macaques. 7-9,16

5.4.2

Pulmonary Multinucleated Cells are Predominantly of Macrophage Origin

In both nonhuman primate species, and at all time points, the bronchointerstitial
pneumonia was accompanied by multinucleated cells in alveoli or on the surface of
alveolar septa. IHC for Iba1 (Figure 5.2 A, B) and pan cytokeratin (Figure 5.2 C, D) on
sections of lung tissue demonstrated that the multinucleated cells were a mixed
population of cells. More than 80% of the multinucleated cells expressed Iba1 indicating
they were of macrophage origin; epithelial syncytia that expressed pan cytokeratin made
up the remainder of the multinucleated cells.

5.4.3

Airway Lesions are More Severe in Common Marmosets

The lesions that developed in bronchi and bronchioles in common marmosets
necropsied 3, 4 or 6 dpi were more severe than those observed in rhesus macaques. The
respiratory epithelium that lined bronchi was rarely damaged in macaques; when
epithelial lesions were present, mild respiratory epithelial degeneration with loss of cilia
was observed (Figure 5.3 A). Multiple bronchioles in macaques were mildly infiltrated by
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neutrophils with fewer macrophages (Figure 5.3 C). Occlusion of bronchioles by large
accumulations of fibrin was not observed in macaques at any time point. At all time
points, affected bronchi and bronchioles in common marmosets were multifocally eroded
and lined by attenuated respiratory epithelium that lacked cilia (Figure 5.3 B). Airways
were often infiltrated predominantly by neutrophils and macrophages which were
occasionally mixed with accumulations of fibrin (Figure 5.3 D).

5.4.4

Higher Amounts of Pulmonary Viral Antigen are Detected in Common
Marmosets
MERS-CoV antigen was detected by IHC in sections of lung from

marmosets and macaques necropsied 3 dpi (Figure 5.4 A, B). Common marmosets had a
significantly higher mean percentage of the lung positively labeled for MERS-CoV
antigen than rhesus macaques, 12.2% versus 3.6%, respectively (P = 0.027) (Figure 5.4
C). In both species, MERS-CoV antigen was detected predominantly in type I and type II
pneumocytes and occasionally in macrophages. The results from the quantification of
pulmonary MERS-CoV antigen fit with previously reported pulmonary viral RNA loads
detected by qRT-PCR. Retrospective pooling and re-analysis of pulmonary viral RNA
load data from rhesus macaque7,9 and common marmoset lung tissues8 show that at 3 dpi
and 6 dpi, common marmosets had pulmonary viral RNA loads up to one thousand times
higher than rhesus macaques necropsied at the same time point (P < 0.0001) (Figure 5.4
D).
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5.4.5

Pulmonary Neutrophil Infiltration is Significantly Higher in Common Marmosets
IHC was performed on lung from marmosets and macaques necropsied at 3 dpi to

detect neutrophils, T lymphocytes, B lymphocytes and macrophages. The percentage of
the pulmonary section that was positively labeled for each type of leukocyte was
quantified by ImageScope (Figure 5.5 A-L). The mean percentage of the lung infiltrated
by neutrophils, as detected by myeloperoxidase IHC, was significantly higher (P < 0.001)
for marmosets (30.5%) than macaques (8.3%). In both species, neutrophils were
numerous in alveolar spaces, with fewer neutrophils in airways, alveolar septa and blood
vessels. The mean percentage of the lung infiltrated by T lymphocytes, B lymphocytes or
macrophages in rhesus macaques as compared to common marmosets was similar (P >
0.05). In both species, T and B lymphocytes exhibited segmental to circumferential
cuffing of blood vessels, bronchi and bronchioles and were widely scattered within
alveolar septa and blood vessels and rarely present in alveolar spaces or airways (Figure
5.6 A-D). In rhesus macaques, lymphoid follicles were adjacent to bronchi or bronchioles.
Lymphoid follicles were rarely observed in common marmosets. In both species,
lymphoid follicles were composed of centrally located B lymphocytes cuffed by T
lymphocytes with variable numbers of macrophages scattered among the B and T
lymphocytes. In macaques and marmosets, macrophages were predominantly identified
within alveolar spaces and septa, while fewer macrophages were found cuffing vascular
walls and airways or were detected within airways and vascular lumina (Figure 5.6 E, F).
The mean percentage of the lung infiltrated by macrophages was higher than that for T or
B lymphocytes in both macaques and marmosets.
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5.4.6

Dipeptidyl Peptidase 4 is Expressed by Similar Cell Types in the Lungs of Rhesus
Macaques and Common Marmosets
To determine whether the difference in lesion severity between common

marmosets and rhesus macaques could be explained by a difference in expression of the
receptor for MERS-CoV, IHC for dipeptidyl peptidase 4 (DPP4) was performed on lung
(Figure 5.7 A, B). In both rhesus macaques and common marmosets, DPP4 was
expressed by pneumocytes, airway epithelium, smooth muscle cells, endothelium, and
macrophages. Similar percentages of each cell type expressed DPP4 in marmosets and
macaques. In both species, MERS-CoV antigen was detected in several of the cell types
that expressed DPP4 in the lung, including type I and type II pneumocytes and alveolar
macrophages.

5.5

Discussion

Epidemiologic data indicate there is marked variation in clinical disease severity
in humans infected with MERS-CoV.14,22,28 This manuscript details the differences and
similarities in pulmonary lesion severity, influx of inflammatory cells into the lungs and
pulmonary viral antigen and RNA loads in two nonhuman primate models of MERS-CoV
disease exhibiting mild versus severe disease.
A mixed population of multinucleated cells were observed in areas of
bronchointerstitial pneumonia in macaques and marmosets; multinucleated cells were
predominantly of macrophage origin while the remainder were of epithelial origin. Other
coronaviruses, including severe acute respiratory syndrome (SARS) coronavirus, which
causes pneumonia in humans, have been associated with the development of
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multinucleated cells of macrophage origin or epithelial origin.12,24 Viral-induced cell-tocell fusion may have caused the formation of the multinucleated cells in the MERS-CoV
inoculated macaques and marmosets. MERS-CoV antigen was detected in the cytoplasm
of scattered macrophages in marmoset and macaque lungs using IHC. Although it is
possible that the viral antigen in some macrophages was due to phagocytosis, it has been
shown that human macrophages can be productively infected with MERS-CoV,30 which
may have resulted in the formation of multinucleated giant cells in the macaques and
marmosets.
Bronchointerstitial pneumonia developed in both rhesus macaques and common
marmosets post-MERS-CoV inoculation; however, the percentage of the lung affected by
lesions and infiltrated by neutrophils was significantly higher in marmosets. The higher
pulmonary viral loads in marmosets may have induced a more robust inflammatory
response resulting in increased neutrophil recruitment. Once in the lungs, neutrophils can
degranulate or release reactive oxygen species, damaging pulmonary tissue and
potentially exacerbating lesions and clinical disease severity.10,13
At 3 dpi, no differences were detected for T lymphocyte, B lymphocyte or
macrophage infiltration into the lungs of marmosets as compared to macaques. However,
upregulation of genes or RNA transcripts associated with proinflammatory mediators has
been shown in pneumonic lung at 3 dpi in both species.7,8 These results fit would be
expected in the early phase of inflammation when an innate immune response is induced
and neutrophils are the predominant effector cell type, prior to activation of the adaptive
immune response.3,11 Marked changes in the numbers of infiltrating lymphocytes and
macrophages usually are not evident until the later stages of inflammation.
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Significantly higher pulmonary viral antigen and viral RNA loads were detected
in marmosets as compared to macaques. The reason for the variation in virus replication
rates in the lungs of these two species is unknown. The difference in pulmonary viral
loads was most likely not caused by differences in DPP4 expression, since the location
and extent of DPP4 expression in the lungs was similar in the macaques and marmosets.
The pulmonary viral load disparity may be due to differences between old world and new
world primates in their susceptibility to MERS-CoV infection and virus replication or
differences in the innate immune response to a viral infection, which could lead to
variations in MERS-CoV-induced disease severity. Differences in viral loads and virus
replication or disease severity between old world and new world primates has been
described for other viral infections.23,25,26 Additionally, anatomical differences between
the respiratory tracts of marmosets and macaques may also influence disease severity.
Alternatively, the more robust inflammatory response in the marmosets may have
promoted MERS-CoV replication, causing higher pulmonary viral loads. It has
previously been described that proinflammatory mediators and pathways can enhance
replication of influenza A virus and herpes simplex virus type 1;15,19,20 similarly, MERSCoV replication may be enhanced in a proinflammatory environment, resulting in the
higher viral loads observed in common marmosets. The increased pulmonary neutrophil
infiltration, rather than the pulmonary viral load alone, in the marmosets likely caused the
increased extent of the lesions, which led to more severe clinical signs. These results
suggest that increased virus replication along with an intense immune response to MERSCoV infection may result in the development of severe respiratory disease.
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The differences in MERS-CoV disease severity between rhesus macaques and
common marmosets allow these two animal models to span the wide range of disease
severity reported in MERS-CoV-infected humans. While both models can be used to
investigate the pathogenesis of this disease, each model may be used for different
applications. Rhesus macaques can serve as a model for mild MERS-CoV disease, which
is increasingly reported in humans infected with MERS-CoV.17,18 Common marmosets
are the more suitable model for severe, potentially fatal, cases of MERS-CoV disease,
which are typically reported in individuals who have an underlying comorbidity or in
older individuals. The severe bronchointerstitial pneumonia that develops in common
marmosets inoculated with MERS-CoV makes marmosets an ideal model for testing the
efficacy of medical countermeasures such as antivirals, therapeutics and vaccines. The
smaller size of common marmosets favors this model for drug studies as it significantly
lowers drug quantities; however, it precludes repeated blood sampling within a short
timeframe and fewer species-specific reagents are available for marmosets as compared
to rhesus macaques. These limitations suggest that rhesus macaques may be a more
suitable model for vaccine studies if repeated analysis of immune parameters is warranted.
Although each model may be better suited for various applications, together, these two
nonhuman primate models will aid in investigations aimed at combating the ongoing
occurrence of human cases of MERS-CoV disease.
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Figure 5.1 MERS-CoV inoculated nonhuman primates develop bronchointerstitial
pneumonia that is histologically similar in character but is more extensive in common
marmosets. Representative sections of lung from a rhesus macaque (A and C) and
common marmoset (B and D) euthanized 3 dpi. A. Unaffected pulmonary tissue
(asterisk) adjacent to a focus of bronchointerstitial pneumonia. B. The lung is diffusely
affected by bronchointerstitial pneumonia. C and D. The microscopic features of the
bronchointerstitial pneumonia are similar in rhesus macaques and common marmosets.
Alveolar septa and lumina are predominantly infiltrated by neutrophils and macrophages
mixed with fibrin, hemorrhage and edema. E and F. The average histologic score for the
bronchointerstitial pneumonia in marmosets is significantly higher, indicating the
pneumonia is more severe and extensive in common marmosets at both 3 dpi (E) and 6
dpi (F). Original magnification, x4 (A and B); x40 (C and D). H&E.
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Figure 5.2 A mixed population of multinucleated cells are widely scattered throughout
the bronchointerstitial pneumonia in rhesus macaques (A and C) and common marmosets
(B and D). A and B. IHC for Iba1 in sections of lung. The majority of the multinucleated
cells express Iba1 (black arrows), indicating the cells are of macrophage origin. Insets
show multinucleated cells that are not macrophages (red arrows), as indicated by their
lack of Iba1 expression. C and D. IHC for pan cytokeratin in sections of lung. The
majority of the multinucleated cells are not of epithelial origin and do not express pan
cytokeratin (black arrows). Insets show multinucleated cells expressing pan cytokeratin
(red arrows), indicating the cells are of epithelial origin. Original magnification, 40x
(main images and insets).
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Figure 5.3 MERS-CoV inoculated common marmosets develop more severe airway
lesions than rhesus macaques. A. Respiratory epithelium in a bronchus exhibits focal loss
of cilia (arrow) in a macaque 3 dpi. Rare inflammatory cells are present in the bronchial
lumen. B. Respiratory epithelial cells in a bronchus are eroded and attenuated (arrows) in
a marmoset 3 dpi. Neutrophils and foamy macrophages infiltrate the bronchial wall and
mix with edema and hemorrhage in the bronchial lumen. C. Neutrophils and foamy
macrophages with minimal edema, hemorrhage and fibrin are present in the wall and
lumen of a bronchiole in a macaque 3 dpi. D. A bronchiole is occluded by a mat of fibrin
(asterisk) mixed with edema, hemorrhage and degenerate leukocytes in a marmoset 4 dpi.
Original magnification, x40 (A-D). H&E.
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Figure 5.4 Common marmoset lungs contain more MERS-CoV antigen than rhesus
macaque lungs. A and B. IHC for MERS-CoV antigen in sections of lung from
nonhuman primates necropsied 3 dpi. Lower amounts of viral antigen are present in
macaques (A) than marmosets (B). Insets show the results of the ImageScope positive
pixel count algorithm for the IHC-labeled lung sections. Red and orange pixels indicate
detection of MERS-CoV antigen; blue pixels indicate tissue does not contain MERS-CoV
antigen. C. The percentage of the lung containing MERS-CoV antigen is higher in
common marmosets, as determined by digital analysis using ImageScope. D. Pulmonary
viral RNA loads are significantly higher in marmosets at both 3 and 6 dpi. Original
magnification, 20x (main images and insets).
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Figure 5.5 Quantification of inflammatory cells in the lung 3 dpi indicates pulmonary
neutrophil infiltration is higher in common marmosets. A and B. IHC for
myeloperoxidase, a marker for neutrophils, in lung sections. C. The percentage of the
lung infiltrated by neutrophils is significantly higher in marmosets. No differences are
noted for pulmonary infiltration by T lymphocytes (D-F), B lymphocytes (G-I) or
macrophages (J-L) between macaques and marmosets. Insets show the results of the
ImageScope positive pixel count algorithm on the IHC-labeled lung sections. Red and
orange pixels indicate detection of specific inflammatory cell markers; cells not
expressing the marker of interest are shown as blue pixels. Original magnification, 20x
(main images and insets).
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Figure 5.6 The location of inflammatory cells in the lung is similar in rhesus macaques
and common marmosets. T lymphocytes are present on the periphery of lymphoid
follicles (A), cuff blood vessels and are found in alveolar septa (B). B lymphocytes form
lymphoid follicles near airways (C) and are found in alveolar septa (D). Macrophages are
common in alveolar septa and lumina (E and F). IHC for CD3 (A and B), CD20 (C and
D) and Iba1 (E and F) in sections of lung 3 dpi. Original magnification, x40 (A-F).
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Figure 5.7 DPP4 is expressed by the same cell types in rhesus macaques and common
marmosets in the lung. IHC for DPP4 on sections of lung show DPP4 is expressed by
airway epithelium and smooth muscle cells in macaques (A) and marmosets (B). Insets
show pneumocytes expressing DPP4. Original magnification, 40x (main images and
insets).
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CHAPTER 6. SUMMARY AND FUTURE DIRECTIONS

6.1

Summary of Research Findings and Future Directions

A large percentage of infectious disease outbreaks have been caused by emerging
viral pathogens; the number of these outbreaks reported has been rising nearly every
decade since the 1940’s.4,5 Since many of these emerging viruses are transmitted from
wildlife reservoirs to humans, it is no surprise that changes that have led to increased
interactions between humans and animals, such as deforestation and urban sprawl, have
been reported in association with disease outbreaks.2,3 As of yet, there are no accurate
methods to pinpoint the geographic location where the next virus will emerge.
Furthermore, it is currently not feasible to predict the next wildlife species that will
transmit a novel virus to humans, nor is it possible to prevent human contact with
potential wildlife reservoirs. It has been estimated that there are at least 320,000 viruses
in mammals alone which have yet to be discovered and we have no clue as to which of
these viruses will have zoonotic potential.1 As such, viral infections will continue to
emerge and cause disease in humans. Since many of these emerging viruses cause
significant disease or death in humans it is vital to study the pathology and
pathogenesis of these novel viruses as they are discovered in order to detect patterns in
their mechanisms of disease. This information could then be used to develop broad
spectrum antivirals or new approaches to rapid vaccine development that could help
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quench outbreaks as they arise. Therefore, the purpose of the research presented here was
to use animal models to characterize the respiratory tract pathology and pathogenesis of
two emergent viral respiratory infections. Additionally, since MERS-CoV was just
isolated for the first time in 2012, the aim was also to evaluate recently developed animal
models of MERS-CoV infection.
In regard to Nipah virus, our initial research on the late stages of Nipah virus
disease in hamsters prompted us to study the early pathogenesis of Nipah virus in order to
identify the initial target organs and target cells. In our early pathogenesis study, Nipah
virus first targeted the lung and nasal cavity and virus replication was detected in the
respiratory tract by 8 hpi. However, by 48 hpi we still did not detect infectious virus or
virus replication in the brain or infection of blood vessels in organs other than the lung.
These results suggested that antivirals aimed at inhibiting virus replication would be of
most benefit if rapidly administered into the respiratory tract and that early treatment may
prevent virus replication in the brain and widespread infection of the vasculature, thus
lessening disease severity. This could be tested by administering an antiviral to groups of
hamsters at a scheduled time point post Nipah virus inoculation, such as either 4, 8, 16,
24, 32 or 48 hours post inoculation and then scoring clinical signs on a daily basis and
analyzing tissues and blood for virus dissemination, virus replication and lesion severity
at scheduled endpoints.
The studies reported here focused on the respiratory component of Nipah virus
disease; however, neurologic disease and encephalitis also play an important role in
human Nipah virus infections. Therefore, it would be valuable to study virus
dissemination to, and the pathogenesis of, Nipah virus disease in the central nervous
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system. Our Nipah virus early pathogenesis study concluded at the 48 hour post
inoculation time point, which was prior to the development of lesions in the central
nervous system. Thus, an experiment similar to the early pathogenesis study, but which
would document disease development in the central nervous system and blood vessels in
multiple organs over time in Syrian hamsters, would be especially useful. Sampling of
hamsters at consecutive time points, such as every 8 hours, from 2 days post inoculation
to development of end-stage clinical disease would provide additional insight into how
Nipah virus disseminates from the respiratory tract to blood vessels in essentially every
organ and to the central nervous system.
Since MERS-CoV was only first identified in 2012, there is still much to learn
about this virus in terms of the lesions it causes, its transmission routes, pathogenesis and
identification of host enzymes or co-factors that aid virus uptake into host cells or virus
replication. In this dissertation we focused on the comparative respiratory tract pathology
of available animal models of MERS-CoV infection. In nonhuman primate models we
noticed differences in the disease severity that developed post MERS-CoV inoculation,
which appeared to be associated with increased virus replication and a more robust
immune response to virus replication. Future studies should focus on pinpointing the
cause of the increased virus replication rate in common marmosets because of its
association with severe, potentially lethal disease. Rhesus macaques and common
marmosets have an identical amino acid structure in the region of DPP4 that binds the
MERS-CoV spike protein and exhibit similar patterns of DPP4 expression in the lung.
This suggests that differences in virus replication rates are unlikely to be caused by
differences in the ability of MERS-CoV to bind to the DPP4 of these two species. Further
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research could focus on mechanisms of virus entry into host cells, identification of
cellular machinery that is used for virus replication or which could inhibit or slow virus
replication, and the acute immune response to MERS-CoV. Differences in any of these
components between rhesus macaques and common marmosets could be responsible for
the variation in the MERS-CoV replication rates. Once this knowledge is available, it
could be used to limit virus replication, potentially lessening disease severity and the case
fatality rate.
Although several animal models of MERS-CoV have been developed, we still do
not know which of these models best recapitulates MERS-CoV disease in humans.
Therefore, procuring and studying autopsy data from fatal human cases would provide
vital information on the pathogenesis of MERS-CoV disease in naturally acquired
infections. Furthermore, although the pathology of MERS-CoV has been documented in
experimentally inoculated dromedary camels, it would be interesting to determine if the
same lesions are observed in naturally infected dromedary camels in the Middle East.
This could be analyzed by performing necropsies on dromedary camels that are actively
shedding infectious virus. Additionally, transmission studies using one or more of the
available animal models of MERS-CoV infection could help determine how MERS-CoV
is transmitted from wildlife reservoirs to humans and among humans.

6.2

Conclusion

The research presented here shows how the development and characterization of
animal models of viral infections helps elucidate the pathology and pathogenesis of
emerging viruses. Once developed, these animal models can then be used to determine
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routes of viral shedding and transmission, decipher the best sample types for diagnosing
infections, identify the most effective route for administering antivirals or vaccines and
be used to test antiviral or vaccine efficacy. Together, this information aids in the overall
goal of managing and mitigating current and future emerging viral infections.
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